



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

03 May 2022
EMA/CHMP/149023/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 21-24 February 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	8
1.1.	Welcome and declarations of interest of members, alternates and experts	8
1.2.	Adoption of agenda.....	8
1.3.	Adoption of the minutes	8
2.	Oral Explanations	9
2.1.	Pre-authorisation procedure oral explanations	9
2.1.1.	arimoclomol - Orphan - EMEA/H/C/005203	9
2.2.	Re-examination procedure oral explanations	9
2.2.1.	Ipique - bevacizumab - EMEA/H/C/005433	9
2.3.	Post-authorisation procedure oral explanations.....	9
2.4.	Referral procedure oral explanations	9
3.	Initial applications	10
3.1.	Initial applications; Opinions.....	10
3.1.1.	Amversio - betaine anhydrous - EMEA/H/C/005637	10
3.1.2.	Dimethyl fumarate Neuraxpharm - dimethyl fumarate - EMEA/H/C/006039.....	10
3.1.3.	Dimethyl fumarate Mylan - dimethyl fumarate - EMEA/H/C/005956.....	10
3.1.4.	Dimethyl fumarate Polpharma - dimethyl fumarate - EMEA/H/C/005955	11
3.1.5.	PreHevbri - hepatitis B surface antigen - EMEA/H/C/005466	11
3.1.6.	Inpremia - insulin human (rDNA) - EMEA/H/C/005331.....	12
3.1.7.	Kapruvia - difelikefalin - EMEA/H/C/005612	12
3.1.8.	Kimtrak - tebentafusp - Orphan - EMEA/H/C/004929	13
3.1.9.	Orgovyx - relugolix - EMEA/H/C/005353.....	13
3.1.10.	Quiviviq - daridorexant - EMEA/H/C/005634	14
3.1.11.	Sitagliptin Accord - sitagliptin - EMEA/H/C/005598	14
3.1.12.	Truvelog Mix 30 - insulin aspart - EMEA/H/C/005635	14
3.1.13.	Vydura - rimegepant - EMEA/H/C/005725	15
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)	15
3.2.1.	insulin human - Article 58 - EMEA/H/W/005779	15
3.2.2.	dabigatran etexilate - EMEA/H/C/005639.....	16
3.2.3.	insulin human - Article 58 - EMEA/H/W/005780	16
3.2.4.	molnupiravir - EMEA/H/C/005789	16
3.2.5.	pirfenidone - EMEA/H/C/005873	17
3.2.6.	bevacizumab - EMEA/H/C/005574	17
3.2.7.	ranibizumab - EMEA/H/C/005610	17

3.3.	Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)	18
3.3.1.	sutimlimab - Orphan - EMEA/H/C/005776.....	18
3.3.2.	gozetotide - EMEA/H/C/005488	18
3.3.3.	bardoxolone methyl - Orphan - EMEA/H/C/005869	18
3.3.4.	lutetium (177lu) vipivotide tetraxetan - EMEA/H/C/005483	18
3.3.5.	pegfilgrastim - EMEA/H/C/005587	19
3.3.6.	tirzepatide - EMEA/H/C/005620	19
3.3.7.	fosdenopterin - Orphan - EMEA/H/C/005378	19
3.3.8.	plerixafor - EMEA/H/C/005943	19
3.3.9.	ruxolitinib - EMEA/H/C/005843	20
3.3.10.	spesolimab - EMEA/H/C/005874	20
3.3.11.	teriflunomide - EMEA/H/C/005960	20
3.3.12.	deucravacitinib - EMEA/H/C/005755.....	20
3.3.13.	bevacizumab - EMEA/H/C/005534	20
3.3.14.	olipudase alfa - PRIME - Orphan - EMEA/H/C/004850	21
3.3.15.	loncastuximab tesirine - Orphan - EMEA/H/C/005685	21
3.4.	Update on on-going initial applications for Centralised procedure.....	21
3.4.1.	teriparatide - EMEA/H/C/005793	21
3.4.2.	mobocertinib - EMEA/H/C/005621	22
3.4.3.	iodine (131I) omburtamab - Orphan - EMEA/H/C/005499.....	22
3.4.4.	germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/005165	22
3.4.5.	trastuzumab - EMEA/H/C/005880	22
3.4.6.	trastuzumab - EMEA/H/C/005066	23
3.5.	Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004.....	23
3.5.1.	Aduhelm - aducanumab - EMEA/H/C/005558	23
3.5.2.	Ipique - bevacizumab - EMEA/H/C/005433	23
3.6.	Initial applications in the decision-making phase.....	24
3.6.1.	Padcev - enfortumab vedotin - EMEA/H/C/005392	24
3.6.2.	Yselyt - linzagolix choline - EMEA/H/C/005442	24
3.7.	Withdrawals of initial marketing authorisation application.....	24
3.7.1.	Dimherity - dimethyl fumarate - EMEA/H/C/006042.....	24

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 25

4.1.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion	25
4.1.1.	Ilumetri - tildrakizumab - EMEA/H/C/004514/X/0023.....	25
4.1.2.	Lyumjev - insulin lispro - EMEA/H/C/005037/X/0010	25

4.1.3.	Nucala - mepolizumab - EMEA/H/C/003860/X/0042.....	25
4.1.4.	Sogroya - somapacitan - Orphan - EMEA/H/C/005030/X/0001/G	26
4.1.5.	Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0003/G	26
4.2.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues.....	26
4.3.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question.....	27
4.3.1.	Calquence - acalabrutinib - EMEA/H/C/005299/X/0009/G.....	27
4.4.	Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008	27
4.5.	Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008.....	27

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information.....	27
5.1.1.	Beovu - brolocizumab - EMEA/H/C/004913/II/0010	27
5.1.2.	Buvidal - buprenorphine - EMEA/H/C/004651/II/0017.....	28
5.1.3.	Cabometyx - cabozantinib - EMEA/H/C/004163/II/0023	28
5.1.4.	Eylea - aflibercept - EMEA/H/C/002392/II/0077/G.....	28
5.1.5.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0110	29
5.1.6.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0111	29
5.1.7.	Libtayo - cemiplimab - EMEA/H/C/004844/II/0026	30
5.1.8.	Opdivo - nivolumab - EMEA/H/C/003985/II/0100	30
5.1.9.	Opdivo - nivolumab - EMEA/H/C/003985/II/0107	30
5.1.10.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0109	31
5.1.11.	Polivy - polatuzumab vedotin - Orphan - EMEA/H/C/004870/II/0012	31
5.1.12.	Retsevmo - selpercatinib - EMEA/H/C/005375/II/0011.....	31
5.1.13.	Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0041 ..	32
5.1.14.	Verzenios - abemaciclib - EMEA/H/C/004302/II/0013	32
5.1.15.	Xalkori - crizotinib - EMEA/H/C/002489/II/0072	33
5.1.16.	Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0042	33
5.1.17.	Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0046	34
5.1.18.	Zerbaxa - ceftolozane / tazobactam - EMEA/H/C/003772/II/0036	34
5.1.19.	WS2065 Delstrigo - doravirine / lamivudine / tenofovir disoproxil - EMEA/H/C/004746/WS2065/0026 Pifeltro - doravirine - EMEA/H/C/004747/WS2065/001935	
5.1.20.	WS2113 Opdivo - nivolumab - EMEA/H/C/003985/WS2113/0108 Yervoy - ipilimumab - EMEA/H/C/002213/WS2113/0090.....	35
5.2.	Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008.....	36

5.2.1.	Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0058/G	36
5.3.	Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008.....	36
6.	Medical devices	36
6.1.	Ancillary medicinal substances - initial consultation	36
6.2.	Ancillary medicinal substances – post-consultation update	36
6.3.	Companion diagnostics – initial consultation.....	37
6.4.	Companion diagnostics – follow-up consultation.....	37
7.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	37
7.1.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	37
8.	Pre-submission issues	37
8.1.	Pre-submission issue.....	37
8.1.1.	niraparib tosylate monohydrate, abiraterone acetate - H0005932.....	37
8.1.2.	polihexanide - H0005858	37
8.1.3.	Request for combination pack – H0005999	38
8.2.	Priority Medicines (PRIME).....	38
8.2.1.	List of applications received	38
8.2.2.	Recommendation for PRIME eligibility.....	38
9.	Post-authorisation issues	38
9.1.	Post-authorisation issues	38
9.1.1.	Comirnaty - tozinameran - EMEA/H/C/005735/II/0093	38
9.1.2.	Comirnaty - tozinameran - EMEA/H/C/005735/II/0104	39
9.1.3.	Comirnaty - tozinameran - EMEA/H/C/005735/II/0111	39
9.1.4.	Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0042 ..	39
9.1.5.	Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0047 ..	40
9.1.6.	Defitelio - defibrotide - EMEA/H/C/002393/S/0057	40
9.1.7.	Vivanza – vardenafil – EMEA/H/C/000488.....	41
9.1.8.	Remicade EMEA/H/C/000240, Flixabi EMEA/H/C/004020, Inflectra EMEA/H/C/002778, Remsima EMEA/H/C/002576, Zessly EMEA/H/C/004647 - Infliximab	41
9.1.9.	Skysona – elivaldogene autotemcel – ATMP - EMEA/C/H/003690	41
9.1.10.	Ocaliva - obeticholic acid - EMEA/H/C/004093/II/0030, Orphan	42
10.	Referral procedures	42
10.1.	Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004.....	42
10.2.	Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004..	42
10.3.	Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004	42

10.4.	Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC.....	43
10.4.1.	Nasolam – midazolam - EMEA/H/A-29(4)/1511	43
10.5.	Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....	43
10.6.	Community Interests - Referral under Article 31 of Directive 2001/83/EC.....	43
10.7.	Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....	43
10.8.	Procedure under Article 107(2) of Directive 2001/83/EC.....	43
10.9.	Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003	43
10.10.	Procedure under Article 29 of Regulation (EC) 1901/2006.....	43
10.11.	Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008	44
11.	Pharmacovigilance issue	44
11.1.	Early Notification System.....	44
12.	Inspections	44
12.1.	GMP inspections.....	44
12.2.	GCP inspections	44
12.3.	Pharmacovigilance inspections.....	44
12.4.	GLP inspections.....	44
13.	Innovation Task Force	44
13.1.	Minutes of Innovation Task Force.....	44
13.2.	Innovation Task Force briefing meetings	45
13.3.	Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004.....	45
13.4.	Nanomedicines activities	45
14.	Organisational, regulatory and methodological matters	45
14.1.	Mandate and organisation of the CHMP	45
14.2.	Coordination with EMA Scientific Committees	45
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC).....	45
14.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups.....	45
14.3.1.	Biologics Working Party (BWP)	45
14.3.2.	Name Review Group (NRG).....	46
14.3.3.	Scientific Advice Working Party (SAWP).....	46
14.3.4.	Oncology Working Party (ONCWP)	46
14.3.5.	SWP Response to CMDh regarding medicinal products with genotoxic potential.....	46
14.3.6.	Re-evaluation of Bisphenol A (BPA) - SWP comment to EFSA public consultation	46

14.3.7.	SAG Infectious Diseases	47
14.3.8.	SAG Vaccines	47
14.3.9.	Nomination of ETF co-chair and representatives from CHMP	47
14.4.	Cooperation within the EU regulatory network.....	47
14.4.1.	Revision of pharmaceutical legislation	47
14.5.	Cooperation with International Regulators	47
14.6.	Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee	48
14.7.	CHMP work plan	48
14.8.	Planning and reporting	48
14.9.	Others	48
15.	Any other business	48
15.1.	AOB topic	48
15.1.1.	Update on COVID-19.....	48
15.1.2.	COVID-19 vaccine (inactivated, adjuvanted, adsorbed) - EMEA/H/C/006019	48
List of participants		49
Explanatory notes		55

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

Slovenia gave a PROXY to Austria.

1.2. Adoption of agenda

CHMP agenda for 21-24 February 2022.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 24-27 January 2022.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 14 February 2022.

The CHMP adopted the minutes of the January Plenary meeting as well as the minutes from the February PROM meeting.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. arimoclomol - Orphan - EMEA/H/C/005203

Orphazyme A/S; treatment of Niemann-Pick disease type C (NPC)

Scope: Oral explanation

Action: Oral explanation to be held on 23 February 2022 at 16:00

Participation of patient representatives.

List of Outstanding Issues adopted on 16.09.2021. List of Questions adopted on 25.03.2021.

An oral explanation was held on 23 February 2022. The presentation by the applicant focused on the clinical data in support of the application.

2.2. Re-examination procedure oral explanations

2.2.1. Ipique - bevacizumab - EMEA/H/C/005433

Rotterdam Biologics B.V.; indicated in adults for the treatment of neovascular macular degeneration associated with aging and diabetes.

Scope: Oral explanation

Action: Oral explanation to be held on 23 February 2022 at 09:00.

Opinion adopted on 11.11.2021. List of Outstanding Issues adopted on 20.05.2021. List of Questions adopted on 17.09.2020.

An oral explanation was held on 23 February 2022. The presentation by the applicant focused on the clinical data in support of the application.

See 3.5.

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Amversio - betaine anhydrous - EMEA/H/C/005637

SERB SA; treatment of homocystinuria

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Cystadane

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on 22.04.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.2. Dimethyl fumarate Neuraxpharm - dimethyl fumarate - EMEA/H/C/006039

Laboratorios Lesvi S.L.; treatment of multiple sclerosis

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of TECFIDERA, Duplicate of Dimethyl fumarate Polpharma

List of Outstanding Issues adopted on 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 22 February 2022.

The summary of opinion was circulated for information.

3.1.3. Dimethyl fumarate Mylan - dimethyl fumarate - EMEA/H/C/005956

Mylan Ireland Limited; treatment of multiple sclerosis

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of TECFIDERA

List of Outstanding Issues adopted on 27.01.2022. List of Questions adopted on 14.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 21 February 2022.

The summary of opinion was circulated for information.

3.1.4. Dimethyl fumarate Polpharma - dimethyl fumarate - EMEA/H/C/005955

Zakłady Farmaceutyczne Polpharma S.A.; treatment of multiple sclerosis

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of TECFIDERA

List of Outstanding Issues adopted on 27.01.2022. List of Questions adopted on 14.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 22 February 2022.

The summary of opinion was circulated for information.

3.1.5. PreHevbri - hepatitis B surface antigen - EMEA/H/C/005466

VBI Vaccines B.V.; indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.09.2021. List of Questions adopted on 22.04.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.6. Inprezia - insulin human (rDNA) - EMEA/H/C/005331

Baxter Holding B.V.; treatment of patients with diabetes mellitus who require intravenous insulin

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.03.2021. List of Questions adopted on 23.07.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 18 February 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.7. Kapruvia - difelikefalin - EMEA/H/C/005612

Vifor Fresenius Medical Care Renal Pharma France; treatment of pruritus

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that difelikefalin is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.8. Kimmtrak - tebentafusp - Orphan - EMEA/H/C/004929

Accelerated assessment

Immunocore Ireland Limited; treatment of uveal melanoma

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.01.2022. List of Questions adopted on 09.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that tebentafusp is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.9. Orgovyx - relugolix - EMEA/H/C/005353

Myovant Sciences Ireland Limited; treatment of adult patients with advanced prostate cancer.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that relugolix is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.10. Quviviq - daridorexant - EMEA/H/C/005634

Idorsia Pharmaceuticals Deutschland GmbH; treatment of insomnia

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that daridorexant is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.11. Sitagliptin Accord - sitagliptin - EMEA/H/C/005598

Accord Healthcare S.L.U.; treatment of type 2 diabetes mellitus

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Januvia

List of Outstanding Issues adopted on 16.12.2021, 16.09.2021, 20.05.2021. List of Questions adopted on 17.09.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.12. Truvelog Mix 30 - insulin aspart - EMEA/H/C/005635

sanofi-aventis groupe; treatment of diabetes mellitus

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 27.01.2022. List of Questions adopted on 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendations dated 16 February 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.13. [Vydura - rimegepant - EMEA/H/C/005725](#)

Biohaven Pharmaceutical Ireland DAC; management of migraine

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 11.11.2021. List of Questions adopted on 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that rimegepant is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 23 February 2022.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. [insulin human - Article 58 - EMEA/H/W/005779](#)

treatment of diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 11.11.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. dabigatran etexilate - EMEA/H/C/005639

prevention of venous thromboembolic events

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 12.11.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult the PKWP and adopted a list of questions to this group.

3.2.3. insulin human - Article 58 - EMEA/H/W/005780

treatment of diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 11.11.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.4. molnupiravir - EMEA/H/C/005789

Treatment of coronavirus disease 2019 (COVID-19)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.12.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

3.2.5. [pirfenidone - EMEA/H/C/005873](#)

indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.09.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. [bevacizumab - EMEA/H/C/005574](#)

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.

First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.

First-line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of outstanding issues; Letter by the applicant dated 15 February 2022, requesting an extension to the clock stop to respond to the list of outstanding issues to be adopted in February 2022.

Action: For adoption

List of Questions adopted on 22.04.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues with a specific timetable.

3.2.7. [ranibizumab - EMEA/H/C/005610](#)

treatment of neovascular age-related macular degeneration in adults

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.09.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. sutimlimab - Orphan - EMEA/H/C/005776

Genzyme Europe BV; treatment of haemolysis in adult patients with cold agglutinin disease (CAD)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. gozetotide - EMEA/H/C/005488

indicated for the identification of prostate-specific membrane antigen (PSMA)-positive lesions after radiolabelling with gallium-68

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. bardoxolone methyl - Orphan - EMEA/H/C/005869

Reata Ireland Limited; treatment of chronic kidney disease

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. lutetium (177lu) vipivotide tetraxetan - EMEA/H/C/005483

treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. [pegfilgrastim - EMEA/H/C/005587](#)

treatment of neutropenia

Scope: List of questions; Letter by the applicant dated 16 February 2022, requesting an extension to the clock stop to respond to the list of questions to be adopted in February 2022.

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions with a specific timetable.

3.3.6. [tirzepatide - EMEA/H/C/005620](#)

treatment of adults with type 2 diabetes mellitus

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. [fosdenopterin - Orphan - EMEA/H/C/005378](#)

Accelerated assessment

Comharsa Life Sciences Ltd; treatment of molybdenum cofactor deficiency type A

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. [plerixafor - EMEA/H/C/005943](#)

treatment of lymphoma and multiple myeloma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. ruxolitinib - EMEA/H/C/005843

treatment of non-segmental vitiligo

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.10. spesolimab - EMEA/H/C/005874

treatment of flares in adult patients with generalised pustular psoriasis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.11. teriflunomide - EMEA/H/C/005960

treatment of multiple sclerosis (MS)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.12. deucravacitinib - EMEA/H/C/005755

treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.13. bevacizumab - EMEA/H/C/005534

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.

First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.

First-line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.14. olipudase alfa - PRIME - Orphan - EMEA/H/C/004850

Accelerated assessment

Genzyme Europe BV; Treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.15. loncastuximab tesirine - Orphan - EMEA/H/C/005685

FGK Representative Service GmbH; treatment of adult patients with relapsed or refractory large B-cell lymphoma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. teriparatide - EMEA/H/C/005793

treatment of osteoporosis

Scope: Letter by the applicant dated 3 February 2022, requesting an extension to the clock stop to respond to the list of questions adopted in May 2021.

Action: For adoption

List of Questions adopted on 20.05.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in May 2021.

3.4.2. [mobocertinib - EMEA/H/C/005621](#)

Treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Scope: Letter by the applicant dated 01 February 2022, requesting an extension to the clock stop to respond to the list of questions adopted in November 2021.

Action: For adoption

List of Questions adopted on 11.11.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in November 2021.

3.4.3. [iodine \(131I\) omburtamab - Orphan - EMEA/H/C/005499](#)

Y-Mabs Therapeutics A/S; treatment of neuroblastoma

Scope: Request by the applicant dated 03 February 2022 for an extension to the clock stop to respond to the list of questions adopted in September 2021.

Action: For adoption

List of Questions adopted on 16.09.2021.

The CHMP did not agree to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in September 2021.

3.4.4. [germanium \(68Ge\) chloride / gallium \(68Ga\) chloride - EMEA/H/C/005165](#)

indicated for in vitro labelling of kits for radiopharmaceutical preparation

Scope: Request by the applicant dated 18 February 2022 for an extension to the clock stop to respond to the list of questions adopted in December 2021.

Action: For adoption

List of Questions adopted on 16.12.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in December 2021.

3.4.5. [trastuzumab - EMEA/H/C/005880](#)

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Request by the applicant dated 17 February 2022 for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

3.4.6. trastuzumab - EMEA/H/C/005066

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Request by the applicant dated 17 February 2022 for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022, 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Aduhelm - aducanumab - EMEA/H/C/005558

Biogen Netherlands B.V.; Alzheimer's disease

Scope: Appointment of rapporteurs, re-examination timetable

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 16.12.2021. List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 25.02.2021.

The CHMP appointed a re-examination Rapporteur and a re-examination Co-Rapporteur.

The CHMP adopted the re-examination timetable.

3.5.2. Ipique - bevacizumab - EMEA/H/C/005433

Rotterdam Biologics B.V.; indicated in adults for the treatment of neovascular macular degeneration associated with aging and diabetes.

Scope: Opinion

Action: For adoption

Opinion adopted on 11.11.2021. List of Outstanding Issues adopted on 20.05.2021. List of Questions adopted on 17.09.2020.

See 2.2

An oral explanation was held on 23 February 2022. The presentation by the applicant focused on the clinical data in support of the application.

The Committee adopted a negative opinion by majority (21 negative votes out of 29 votes) recommending the refusal of the granting of the marketing authorisation. The CHMP assessment report was adopted.

The divergent position (Elita Poplavska, Margareta Bego, Outi Mäki-Ikola, Kristina Dunder, Armando Genazzani, Sinan Sarac, Edward Laane, Johann Lodewijk Hillege) was appended

to the opinion.

3.6. Initial applications in the decision-making phase

3.6.1. Padcev - enfortumab vedotin - EMEA/H/C/005392

Astellas Pharma Europe B.V.; treatment of locally advanced (LA) or metastatic urothelial cancer (mUC)

Scope: Update on the status of this application. Revised Opinion.

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 16.12.2021. List of Outstanding Issues adopted on 14.09.2021. List of Questions adopted on 22.06.2021.

The Committee adopted a revised positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

3.6.2. Yselty - linzagolix choline - EMEA/H/C/005442

ObsEva Ireland Ltd; for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids

Scope: List of Questions

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 16.12.2021. List of Outstanding Issues adopted on 11.11.2021, 16.09.2021. List of Questions adopted on 22.04.2021.

The CHMP adopted a list of questions with a specific timetable.

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Dimherity - dimethyl fumarate - EMEA/H/C/006042

Sandoz GmbH; treatment of multiple sclerosis

Scope: Withdrawal of marketing authorisation application

Action: For information

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of TECFIDERA, Duplicate of Dimethyl fumarate Polpharma

List of Outstanding Issues adopted on 27.01.2022.

The CHMP noted the withdrawal of marketing authorisation application.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Ilumetri - tildrakizumab - EMEA/H/C/004514/X/0023

Almirall S.A

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension application to introduce a new strength (200 mg solution for injection)."

Action: For adoption

List of Questions adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.1.2. Lyumjev - insulin lispro - EMEA/H/C/005037/X/0010

Eli Lilly Nederland B.V.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Annika Folin

Scope: "Extension application. The RMP is updated (version 11.1) accordingly."

Action: For adoption

List of Questions adopted on 14.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP adopted the similarity assessment report.

4.1.3. Nucala - mepolizumab - EMEA/H/C/003860/X/0042

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension application to introduce a new strength of 40 mg for Nucala solution for injection in a pre-filled syringe for subcutaneous use to be used in children aged 6 to 11 years."

Action: For adoption

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on

16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.1.4. Sogroya - somapacitan - Orphan - EMEA/H/C/005030/X/0001/G

Novo Nordisk A/S

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber

Scope: "Extension application to add a new strength of 5 mg/1.5 mL (3.3 mg/mL) grouped with a Type II Quality variation. RMP was updated (version 2.0) accordingly.

Type II variation (B.II.b.1.c)

Type IA variation (B.II.d.1.a)"

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022. List of Questions adopted on 14.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.1.5. Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0003/G

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Sonja Hrabcik

Scope: "Extension application to add a new strength of 80 mg grouped with a type IB variation to add a new pack size for 40 mg strength.

The RMP (version 1.2) is updated in accordance.

Furthermore, the PI is being brought in line with the QRD template version 10.2 to update the local representatives with "United Kingdom (Northern Ireland)."

Action: For adoption

List of Questions adopted on 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

No items

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Calquence - acalabrutinib - EMEA/H/C/005299/X/0009/G

AstraZeneca AB

Rapporteur: Filip Josephson, PRAC Rapporteur: Željana Margan Koletić

Scope: "Extension application to introduce a new pharmaceutical form, film-coated tablet. A.6 - To change the ATC Code of acalabrutinib from L01XE51 to L01EL02."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality, non-clinical and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Beovu - brolocizumab - EMEA/H/C/004913/II/0010

Novartis Europharm Limited

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of visual impairment due to DME for Beovu; as a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.2. Buvidal - buprenorphine - EMEA/H/C/004651/II/0017

Camurus AB

Rapporteur: Peter Kiely, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Tiphaine Vaillant

Scope: "To add the new therapeutic indication of treatment of moderate to severe chronic pain in patients with opioid dependence. As a consequence, sections 4.1, 4.2, 4.5, 5.1 and 6.6 of the SmPC and sections 1, 3 and Instruction for use of the PL are updated accordingly. The updated RMP version 2.1 has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.3. Cabometyx - cabozantinib - EMEA/H/C/004163/II/0023

Ipsen Pharma

Rapporteur: Ingrid Wang, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include monotherapy treatment of adults and adolescent patients aged 12 years and older, with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy for Cabometyx; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.4. Eylea - aflibercept - EMEA/H/C/002392/II/0077/G

Bayer AG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault

Scope: "C.I.6 (Extension of indication) Extension of indication to include the paediatric indication retinopathy of prematurity (ROP) for Eylea; as a consequence, sections 2, 4.1,

4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Separate Package Leaflet is proposed for the guardians of preterm babies. Version 32.1 of the RMP has also been submitted. B.IV.1.a.3.”

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects and the wording of the indication.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.5. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0110

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: “Extension of indication for Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery of adults with locally advanced, inflammatory, or early-stage triple-negative breast cancer at high-risk of recurrence; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 37.1 of the RMP has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee discussed the issues identified in this application, relating to wording of the indication.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.6. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0111

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: “Extension of indication to include the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, stage IIC or stage III melanoma and to include the treatment of adolescents aged 12 years and older with advanced melanoma for Keytruda; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 36.1 of the RMP has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.7. Libtayo - cemiplimab - EMEA/H/C/004844/II/0026

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include monotherapy treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy for Libtayo; sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.8. Opdivo - nivolumab - EMEA/H/C/003985/II/0100

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication for Opdivo to include adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) who are at high risk of recurrence after undergoing radical resection of MIUC; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 23.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021, 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.9. Opdivo - nivolumab - EMEA/H/C/003985/II/0107

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include in combination with fluoropyrimidine- and platinum-based combination chemotherapy the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) for Opdivo based on study CA209648; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 25.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee discussed the issues identified in this application.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.10. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0109

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Keytruda as monotherapy in the treatment of unresectable or metastatic MSI-H or dMMR colorectal, endometrial, gastric, small intestine, biliary, or pancreatic cancer in adults who have received prior therapy. The proposed indication is based on the results from the KEYNOTE-164 (KN164) and KEYNOTE-158 (KN158) trials. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. An updated version of the RMP (Version 34.1) has been submitted."

Action: For adoption

Request for Supplementary Information adopted on 14.10.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.11. Polivy - polatuzumab vedotin - Orphan - EMEA/H/C/004870/II/0012

Roche Registration GmbH

Rapporteur: Alexandre Moreau, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Annika Folin

Scope: "Extension of the indication to include: Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) based on the efficacy and safety data from the Pivotal Phase III study GO39942 (POLARIX). This submission fulfils SOB003 thus supporting the switch from CMA to full MA. Annexes I, II, IIIB are revised. The RMP is also updated."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.12. Retsevmo - selpercatinib - EMEA/H/C/005375/II/0011

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the first-line treatment of RET fusion-positive NSCLC for Retsevmo based on results from study LIBRETTO-001, an open-label, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumours; as a consequence, sections 4.1, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects. The Committee adopted a request for supplementary information with a specific timetable.

5.1.13. [Spikevax - COVID-19 mRNA vaccine \(nucleoside-modified\) - EMEA/H/C/005791/II/0041](#)

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop

Scope: "Extension of indication to include use in children 6-11 years of age for Spikevax, based on data from study mRNA-1273-P204, an ongoing Phase 2/3, 2-part, open-label, dose-escalation, age de-escalation and subsequent randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 in healthy children; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. Annex II and the Package Leaflet are updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.14. [Verzenios - abemaciclib - EMEA/H/C/004302/II/0013](#)

Eli Lilly Nederland B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include Verzenios in combination with endocrine therapy for adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022, 14.10.2021, 24.06.2021, 25.02.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by majority (26 positive out of 27 votes) together with the CHMP assessment report and translation timetable.

The divergent position (Armando Genazzani) was appended to the opinion.

The summary of opinion was circulated for information.

5.1.15. Xalkori - crizotinib - EMEA/H/C/002489/II/0072

Pfizer Europe MA EEIG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension of indication to include treatment of paediatric patients (age ≥ 6 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumour (IMT) for Xalkori based on the results from studies ADVL0912 and A8081013; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the ATC code for crizotinib. Moreover, the MAH took the opportunity to implement a minor change in the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 16.09.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.16. Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0042

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Claire Beuneu, CHMP Coordinators: Jan Mueller-Berghaus and Karin Janssen van Doorn, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC, Annex II (Section D) and Package Leaflet are proposed to be updated. As a consequence, the RMP (version 5.1) has been updated to align with the indication extension.

In addition, the applicant has taken the opportunity to make minor editorial corrections throughout the SmPC and package leaflet to align with the current Quality Review of Documents (QRD) template." Request for 1 year of market protection for a new indication

(Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 05.11.2021.

The CHMP was updated on discussions at the CAT. The Committee discussed the issues identified in this application, relating to quality, clinical aspects as well as the RMP.

The Committee endorsed a 2nd request for supplementary information with a specific timetable, as adopted by CAT.

5.1.17. Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0046

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Claire Beuneu, CHMP Coordinators: Jan Mueller-Berghaus and Karin Janssen van Doorn, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) for Yescarta; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.3 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the product information with minor editorial changes." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The CHMP was updated on discussions at the CAT. The Committee discussed the issues identified in this application, relating to quality, clinical aspects as well as the RMP.

The Committee endorsed a request for supplementary information with a specific timetable, as adopted by CAT.

5.1.18. Zerbaxa - ceftolozane / tazobactam - EMEA/H/C/003772/II/0036

Merck Sharp & Dohme B.V.

Rapporteur: Ingrid Wang, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include treatment of paediatric patients aged birth to less than 18 years for Zerbaxa, based on final results from studies MK-7625A-034 (A Phase 2, Randomized, Active Comparator-Controlled, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Pediatric Subjects with Complicated Urinary Tract Infection, Including Pyelonephritis) and MK-7625A-035 (A Phase 2, Randomized, Active Comparator-Controlled, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem in Pediatric Subjects with Complicated Intra-Abdominal Infection).

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 14.10.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects and the SmPC.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.19. WS2065
Delstrigo - doravirine / lamivudine / tenofovir disoproxil - EMEA/H/C/004746/WS2065/0026
Pifeltro - doravirine - EMEA/H/C/004747/WS2065/0019

Merck Sharp & Dohme B.V.

Lead Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include the new indication to the paediatric population weighing at least 35 kgs for Pifeltro and Delstrigo. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP for each product have also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial corrections and to update the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.20. WS2113
Opdivo - nivolumab - EMEA/H/C/003985/WS2113/0108
Yervoy - ipilimumab - EMEA/H/C/002213/WS2113/0090

Bristol-Myers Squibb Pharma EEIG

Lead Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) for Opdivo in combination with Yervoy; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 24.0 of the Opdivo RMP and version 33.0 of the Yervoy RMP have also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0058/G

Teva B.V.

Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication to include treatment of the paediatric population for Lonquex and introduction of an age appropriate presentation in vials; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

Letter from the applicant dated 07 February 2022 requesting an extension to the clock stop to respond to the request for supplementary information adopted in October 2021.

Action: For adoption

Request for Supplementary Information adopted on 14.10.2021, 12.11.2020.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the request for supplementary information adopted in October 2021.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics – initial consultation

No items

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. niraparib tosylate monohydrate, abiraterone acetate - H0005932

is indicated with prednisone or prednisolone for the treatment of adult patients with prostate cancer who have progressed to metastatic castration resistant prostate cancer (mCRPC) and are positive for HRR gene alteration (germline and/or somatic).

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.2. polihexanide - H0005858

Treatment of Acanthamoeba keratitis

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.3. Request for combination pack – H0005999

Treatment of advanced breast cancer

Scope: Request for combination pack

Action: For adoption

The CHMP agreed to the request for a combination pack and adopted the briefing note.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the information.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 3 recommendations for eligibility to PRIME: 3 were denied.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Comirnaty - tozinameran - EMEA/H/C/005735/II/0093

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC of Comirnaty 30 microgram/dose and section 4.8 of the SmPC of Comirnaty 10 microgram/dose in order to update efficacy and safety information after booster dose and to change posology recommendations for booster use from "individuals 18 years of age and older" to "individuals 16 years of age and older", based on interim results from study C4591031, this is a randomized, placebo-controlled, phase 3 booster efficacy study involving participants \geq 16 years of age who completed the primary series of BNT162b2 30 μ g in study C4591001, published literature data and post-marketing safety data. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.2. Comirnaty - tozinameran - EMEA/H/C/005735/II/0104

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update immunogenicity, safety and efficacy information regarding heterologous vaccination (both in the primary series and for booster vaccinations) based on published literature data; the Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.3. Comirnaty - tozinameran - EMEA/H/C/005735/II/0111

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "Update of section 4.2 of the SmPC of Comirnaty 30 microgram/dose in order to change posology recommendations for booster use from "individuals 18 years of age and older" to "individuals 12 years of age and older", based on real world evidence collected by the Ministry of Health of Israel and published literature data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.4. Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0042

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus

Scope: "Update of sections 4.2 and 5.1 of the SmPC in order to include information on heterologous boosting using a 50 ug dose of Spikevax to boost subjects that have previously completed a primary vaccination series with any authorised COVID-19 vaccine, and to shorten the duration of the interval between the primary series and the booster dose to 3 months, based on data from the DMID Study 21-0012, a Phase 1/2 heterologous SARS-CoV-2 vaccine dosing (mRNA-1273 booster) study of the various vaccines authorised in the US under Emergency Use Authorisation in participants \geq 18 years old (NCT04889209). In addition, the MAH took the opportunity to implement the WHO-approved INN 'elasomeran' and make minor editorial changes/corrections throughout the product information. The Annex A, the Labelling and the Package Leaflet are amended accordingly."

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022, 16.12.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.5. [Spikevax - COVID-19 mRNA vaccine \(nucleoside-modified\) - EMEA/H/C/005791/II/0047](#)

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus

Scope: "Update of section 5.1 of the SmPC in order to introduce data on the immunogenicity of Spikevax against the B.1.617.2 (Delta) variant in adults and children, based on cross-neutralisation data from studies mRNA-1273-P301 (an ongoing Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older - NCT04470427), mRNA-1273-P201B (Part B of an ongoing Phase 2a, Randomized, Observer-Blind, Placebo-Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older - NCT04405076), and mRNA-1273-P204 (an ongoing Phase 2/3, 2-part, open-label, dose-escalation, age de-escalation and subsequent randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 in healthy children - NCT04796896)."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.6. [Defitelio - defibrotide - EMEA/H/C/002393/S/0057](#)

Gentium S.r.l.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: annual re-assessment

Action: For adoption

The Committee discussed the issues identified in this application, relating to the specific obligation as part of the marketing authorisation under exceptional circumstances.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.7. Vivanza – vardenafil – EMEA/H/C/000488

Bayer AG; treatment of erectile dysfunction

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Johann Lodewijk Hillege

Scope: Withdrawal of marketing authorisation

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

The CHMP noted the withdrawal of marketing authorisation.

9.1.8. Remicade EMEA/H/C/000240, Flixabi EMEA/H/C/004020, Inflectra EMEA/H/C/002778, Remsima EMEA/H/C/002576, Zessly EMEA/H/C/004647 - Infliximab

MAHs: various

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Use of live vaccines in infants exposed in utero or during breastfeeding. The DHPC, communication plan and PRAC advice have been adopted via written procedure on 14.02.2022

Action: For information

The CHMP noted the documents, which were adopted via written procedure on 14.02.2022.

9.1.9. Skysona – elivaldogene autotemcel – ATMP - EMEA/C/H/003690

bluebird bio (Netherlands) B.V.; treatment of early cerebral adrenoleukodystrophy

Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder

Scope: Withdrawal of marketing authorisation

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

The CHMP noted the withdrawal of marketing authorisation.

9.1.10. Ocaliva - obeticholic acid - EMEA/H/C/004093/II/0030, Orphan

Intercept Pharma International Limited

Rapporteur: Blanca Garcia-Ochoa

Scope: "Update of section 4.3 of the SmPC in order to include contraindication in patients with decompensated cirrhosis (e.g., Child-Pugh Class B or C) or a prior decompensation event based on the MAH's conclusion that it will not be feasible to establish the safety and efficacy of Ocaliva in these patients from either of the ongoing studies 747-302 and 747-401 listed as Specific Obligations in Annex II. Consequently, dosing instructions for patients with CP-B and CP-C cirrhosis are no longer applicable and section 4.2 has been updated accordingly. In addition, section 4.4 of the SmPC to include a new warning on monitoring and management of patients for possible progression of PBC and other hepatic adverse reactions. The MAH also took the opportunity to remove the outdated term "primary biliary cirrhosis" from section 4.1 and to make editorial changes to sections 4.8, 4.9, 5.1 and Annex IIE to improve clarity and correct typographical errors. The Package Leaflet is updated accordingly. Furthermore, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2"

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Nasolam – midazolam - EMEA/H/A-29(4)/1511

Tiofarma B.V

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Kristina Dunder

Scope: Revised opinion adopted via written procedure on 18.02.2022.

Action: For information

Decentralised procedure number: NL/H/5089/001-003/DC, notification by the Agency of the Netherlands dated 24 September 2021 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC.

Opinion adopted on 27.01.2022.

The CHMP noted the revised documents, which were adopted via written procedure on 18.02.2022.

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

February 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for February 2022

Action: For adoption

The CHMP adopted the EURD list.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP February 2022 meeting to CHMP for adoption:

- 20 reports on products in scientific advice and protocol assistance
- 16 reports on products in pre-authorisation procedures
- 2 reports on products in post-authorisation procedures
- 6 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 15-16 February 2022.

Action: For adoption

The CHMP adopted the table of decisions.

14.3.3. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 07-10 February 2022. Table of conclusions

Action: For information

The CHMP noted the report.

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.4. Oncology Working Party (ONCWP)

Chair: TBC

Proposal for the list of new members for the Oncology Working Party under the new Working Parties Operational Model (WOM).

Action: For adoption

The CHMP adopted the list of new members for the Oncology Working Party under the new Working Parties Operational Model (WOM).

14.3.5. SWP Response to CMDh regarding medicinal products with genotoxic potential

SWP answered questions from CMDh in 2020 on how to deal with the duration of contraception after completion of a therapy using potentially genotoxic medicines. Member states are now receiving variations with regards to these recommendations. CMDh proposed an amendment to the published Q&A.

Action: For adoption

The CHMP adopted the SWP response to CMDh regarding medicinal products with genotoxic potential.

14.3.6. Re-evaluation of Bisphenol A (BPA) - SWP comment to EFSA public consultation

Summary: EFSA launched an open consultation on the draft scientific opinion on the re-evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs with a proposed new TDI value. SWP will provide comments on the draft opinion to share with EFSA some of the concerns related to the methodology and safety assessment that led to the establishment of this new TDI value.

Action: For adoption

The CHMP adopted the SWP comment to EFSA public consultation on the evaluation of Bisphenol A (BPA).

14.3.7. SAG Infectious Diseases

Appointment of SAG Infectious Diseases chair person, based on the outcome of the election organised by the SAG, in accordance to the SAG rules of procedure

Action: For endorsement

CHMP endorsed the appointment of Emilia Cercenado as chair of SAG Infectious Diseases.

14.3.8. SAG Vaccines

Appointment of SAG Vaccines chair person, based on the outcome of the election organised by the SAG, in accordance to the SAG rules of procedure

Action: For endorsement

CHMP endorsed the appointment of Jean-Daniel Lelievre as chair of SAG Vaccines.

14.3.9. Nomination of ETF co-chair and representatives from CHMP

Following implementation of Regulation (EU) 2022/123, Article 15(3) of Regulation (EU) No 2022/123 stipulates that the ETF shall be co-chaired by the chair or vice-chair of the CHMP. In addition, ETF shall also consist of representatives from the CHMP.

Action: For adoption

CHMP noted the request to appoint four CHMP members and a co-chair to ETF. The nominations were endorsed via written procedure after the meeting: Bruno Sepodes as co-chair of ETF and Jan Muller Berghaus, Filip Josephson, Sol Ruiz and Jean-Michel Race as representative of CHMP to ETF.

14.4. Cooperation within the EU regulatory network

14.4.1. Revision of pharmaceutical legislation

Follow-up on new Pharmaceutical Strategy

Action: For discussion

The CHMP noted the follow-up on the new Pharmaceutical Strategy.

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

The CHMP noted the update.

15.1.2. COVID-19 vaccine (inactivated, adjuvanted, adsorbed) - EMEA/H/C/006019

prevention of coronavirus disease-2019 (COVID-19)

Scope: Rolling review 1st interim opinion

Action: For adoption

The CHMP adopted the 1st interim rolling review opinion and adopted a list of questions.

List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 21-24 February 2022 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphly	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Thalia Marie Estrup Blicher	Alternate	Denmark	No participation in final deliberations and voting on	insulin human - Article 58 - EMEA/H/W/005779 insulin human - Article 58 - EMEA/H/W/005780 Sogroya - somapacitan - Orphan - EMEA/H/C/005030/X/0001/G
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Armando Genazzani	Member	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Silvijus Abramavicius	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
Carola de Beaufort	Alternate	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on:	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Mair Powell	Expert - via WebEx*	Ireland	No interests declared	
Niamh Curran	Expert - via WebEx*	Ireland	No interests declared	
Vincent Gazin	Expert - via WebEx*	France	No interests declared	
Anissa Benlazar	Expert - via WebEx*	France	No interests declared	
Stephanie Hueber	Expert - via WebEx*	France	No interests declared	
Nicolas Camhaji	Expert - via WebEx*	France	No participation in discussion, final	Beovu - brolucizumab -

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
			deliberations and voting on	EMA/H/C/004913/II/0010
Melanie Leplay	Expert - via WebEx*	France	No interests declared	
Catherine Deguines	Expert - via WebEx*	France	No interests declared	
Elisabeth Fuerst	Expert - via WebEx*	Austria	No interests declared	
Karl Katholnig	Expert - via WebEx*	Austria	No restrictions applicable to this meeting	
Philipp Janesch	Expert - via WebEx*	Austria	No interests declared	
Franz Rieder-Rommer	Expert - via WebEx*	Austria	No interests declared	
Tjerk Feenstra	Expert - via WebEx*	Austria	No interests declared	
Martin Walter	Expert - via WebEx*	Austria	No interests declared	
Harald Bernsteiner	Expert - via WebEx*	Austria	No interests declared	
Elisabeth Wischnitzki	Expert - via WebEx*	Austria	No interests declared	
Walter Johannes Beiersdorf	Expert - via WebEx*	Austria	No restrictions applicable to this meeting	
Anja Schiel	Expert - via WebEx*	Norway	No interests declared	
Paolo Foggi	Expert - via WebEx*	Italy	No interests declared	
Stephan Lehr	Expert - via WebEx*	Austria	No interests declared	
Joerg Zinserling	Expert - via WebEx*	Germany	No interests declared	
Finbarr Leacy	Expert - via WebEx*	Ireland	No interests declared	
Kairi Rooma	Expert - via WebEx*	Estonia	No interests declared	
Caroline Gjestad	Expert - via WebEx*	Norway	No interests declared	
Linda Trauffer	Expert - via WebEx*	Austria	No interests declared	
Martin Hohenegger	Expert - via WebEx*	Austria	No restrictions applicable to this meeting	
Ieva Rutkovska	Expert - via WebEx*	Latvia	No interests declared	
Janis Kurlovics	Expert - via WebEx*	Latvia	No restrictions applicable to this meeting	
Paula Contreras Alarcón	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Maria Victoria Tudanca Pacios	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Carolina Prieto Fernandez	Expert - via WebEx*	Spain	No interests declared	
Lucia Lopez-Anglada Fernandez	Expert - via WebEx*	Spain	No interests declared	
Macarena Gajardo	Expert - via WebEx*	Spain	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Lourdes Rodriguez Rojas	Expert - via WebEx*	Spain	No interests declared	
Cristina Lucia Rueda Pérez	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Eva Maria Nadal Elduayen	Expert - via WebEx*	Spain	No interests declared	
Luisa Valer	Expert - via WebEx*	Spain	No interests declared	
Martijn van Gils	Expert - via WebEx*	Netherlands	No interests declared	
Miki Hew	Expert - via WebEx*	Netherlands	No interests declared	
Patrick Vrijlandt	Expert - via WebEx*	Netherlands	No interests declared	
Hannelore Samyn	Expert - via WebEx*	Netherlands	No interests declared	
Nienke Rodenhuis	Expert - via WebEx*	Netherlands	No interests declared	
Carla Herberts	Expert - via WebEx*	Netherlands	No interests declared	
Annette Lommel	Expert - via WebEx*	Germany	No interests declared	
Susanne Mueller-Egert	Expert - via WebEx*	Germany	No interests declared	
Hilke Zander	Expert - via WebEx*	Germany	No interests declared	
Sabine Mayrhofer	Expert - via WebEx*	Germany	No interests declared	
Irene Bachmann	Expert - via WebEx*	Germany	No interests declared	
Nora Cascante Estepa	Expert - via WebEx*	Germany	No interests declared	
Anne Isabel Roth	Expert - via WebEx*	Germany	No interests declared	
Sofia Kapanadze	Expert - via WebEx*	Germany	No restrictions applicable to this meeting	
Violette Dirix	Expert - via WebEx*	Belgium	No interests declared	
Edwige Haelterman Brenneisen	Expert - via WebEx*	Belgium	No interests declared	
Inne Crèvecoeur	Expert - via WebEx*	Belgium	No part in discussions, final deliberations and voting on	molnupiravir - EMEA/H/C/005789 Keytruda - pembrolizumab - II/0109, II/110, II/111 Zerbaxa - ceftolozane / tazobactam - EMEA/H/C/003772/ II/0036 WS2065 Delstrigo /Pifeltro
Valerie Lescrainier	Expert - via WebEx*	Belgium	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Jana Klimasová	Expert - via WebEx*	Slovakia	No interests declared	
Anna Kubandová	Expert - via WebEx*	Slovakia	No interests declared	
Jana Schweigertova	Expert - via WebEx*	Slovakia	No interests declared	
Eva Malikova	Expert - via WebEx*	Slovakia	No interests declared	
Nanna Borup Johansen	Expert - via WebEx*	Denmark	No interests declared	
Aaron Emmanuel Sosa Mejia	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Lene Weber Vestermark	Expert - via WebEx*	Denmark	No interests declared	
Anne-Marie Dalseg	Expert - via WebEx*	Denmark	No interests declared	
Susanne Høpner Rasmussen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Deirdre Mannion	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Mette Toftegaard Madsen	Expert - via WebEx*	Denmark	No interests declared	
Mette Linnert Jensen	Expert - via WebEx*	Denmark	No interests declared	
Doris Johanna Hovgaard	Expert - via WebEx*	Denmark	No interests declared	
Anne Hasle Buur	Expert - via WebEx*	Denmark	No interests declared	
Mette Tranholm	Expert - via WebEx*	Denmark	No interests declared	
Line Præst Lauridsen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Simona Teodosiu	Expert - via WebEx*	France	No interests declared	
Nathalie Dumarcet	Expert - via WebEx*	France	No interests declared	
Liora Brunel	Expert - via WebEx*	France	No interests declared	
Antonella Isgrò	Expert - via WebEx*	Italy	No interests declared	
Gabriella Passacquale	Expert - via WebEx*	Italy	No interests declared	
Robert Porszasz	Expert - via WebEx*	Hungary	No interests declared	
Adriana Ammassari	Expert - via WebEx*	Italy	No interests declared	
Luca Santi	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	
Martina Perini	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	
Cristina Migali	Expert - via WebEx*	Italy	No interests declared	
Michela Piezzo	Expert - via WebEx*	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Simona Russo	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	
Sara Galluzzo	Expert - via WebEx*	Italy	No interests declared	
Celine Jumeau	Expert - via WebEx*	France	No interests declared	
	via WebEx*	Patient Representative	No interests declared	
	via WebEx*	Patient Representative	No interests declared	
Gaja Lesnicar Pucko	Expert - via WebEx*	Slovenia	No interests declared	
Mirjam Hinterleitner	Expert - via WebEx*	Austria	No interests declared	
Roderick Houwen	Expert - via WebEx*	Netherlands	No restrictions applicable to this meeting	
Yuansheng Sun	Expert - via WebEx*	Germany	No interests declared	
Eva Agurell	Expert - via WebEx*	Sweden	No interests declared	
Helena Back	Expert - via WebEx*	Sweden	No interests declared	
Helena Faust	Expert - via WebEx*	Sweden	No interests declared	
Charlotta Bergquist	Expert - via WebEx*	Sweden	No interests declared	
Irja Lutsar	Expert - via WebEx*	Estonia	No interests declared	
Vita Gulevska	Expert - via WebEx*	Latvia	No interests declared	
Koenraad Norga	Expert - via WebEx*	Belgium	No interests declared	
Gerhard Kieselbach	Expert - via Telephone*	Austria	No interests declared	
Filip Kukulski	Expert - via WebEx*	Health Canada	No interests declared	
Violetta Skalski	Expert - via WebEx*	Health Canada	No interests declared	
Evelyn Soo	Expert - via WebEx*	Health Canada	No interests declared	
Mohit Khara	Expert - via WebEx*	TGA Australia	No interests declared	
Megan Hickie	Expert - via WebEx*	TGA Australia	No interests declared	
Meeting run with the help of EMA staff				

*Experts were evaluated against the product(s) they have been invited to talk about

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths,

formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a

particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

Satellite groups / other committees (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

Invented name issues (section 14.3)

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/



03 May 2022
EMA/CHMP/116112/2022

Annex to 21-24 February 2022 CHMP Minutes

Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES.....	3
A.1. ELIGIBILITY REQUESTS.....	3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications.....	3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION.....	3
B. POST-AUTHORISATION PROCEDURES OUTCOMES.....	3
B.1. Annual re-assessment outcomes	3
B.1.1. Annual reassessment for products authorised under exceptional circumstances.....	3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES	4
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal	4
B.2.2. Renewals of Marketing Authorisations for unlimited validity.....	4
B.2.3. Renewals of Conditional Marketing Authorisations.....	6
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES	7
B.4. EPARs / WPARs.....	10
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES.....	11
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects	11
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	17
B.5.3. CHMP-PRAC assessed procedures.....	31
B.5.4. PRAC assessed procedures	38
B.5.5. CHMP-CAT assessed procedures.....	45
B.5.6. CHMP-PRAC-CAT assessed procedures.....	46
B.5.7. PRAC assessed ATMP procedures.....	46
B.5.8. Unclassified procedures and worksharing procedures of type I variations.....	46
B.5.9. Information on withdrawn type II variation / WS procedure	49
B.5.10. Information on type II variation / WS procedure with revised timetable.....	49
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION.....	51
B.6.1. Start of procedure for New Applications: timetables for information.....	51
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information.....	52



B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information.....	52
B.6.4. Annual Re-assessments: timetables for adoption.....	53
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed.....	54
B.6.6. VARIATIONS – START OF THE PROCEDURE.....	56
B.6.7. Type II Variations scope of the Variations: Extension of indication	56
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects	57
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	61
B.6.10. CHMP-PRAC assessed procedures	66
B.6.11. PRAC assessed procedures.....	70
B.6.12. CHMP-CAT assessed procedures.....	72
B.6.13. CHMP-PRAC-CAT assessed procedures	73
B.6.14. PRAC assessed ATMP procedures	73
B.6.15. Unclassified procedures and worksharing procedures of type I variations	73
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY	75
B.7.1. Yearly Line listing for Type I and II variations.....	75
B.7.2. Monthly Line listing for Type I variations	75
B.7.3. Opinion on Marketing Authorisation transfer (MMD only)	75
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only).....	75
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only).....	75
B.7.6. Notifications of Type I Variations (MMD only)	75
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)	75
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed).....	75
E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES	75
E.1. Time-Tables – starting & ongoing procedures: For information	75
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver.....	75
G. ANNEX G	75
G.1. Final Scientific Advice (Reports and Scientific Advice letters):	75
G.2. PRIME	75
G.2.1. List of procedures concluding at 21-24 February 2022 CHMP plenary:	76
G.2.2. List of procedures starting in February 2022 for March 2022 CHMP adoption of outcomes	76
H. ANNEX H - Product Shared Mailboxes – e-mail address.....	76

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for February 2022: For adoption	Adopted
---	---------

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for February 2022: For adoption	Adopted
---	---------

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Defitelio - defibrotide - EMEA/H/C/002393/S/0057, Orphan Gentium S.r.l., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 24.02.2022.	Request for supplementary information adopted with a specific timetable. See 9.1
--	---

Lojuxta - lomitapide - EMEA/H/C/002578/S/0048 Amryt Pharmaceuticals DAC, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 16.12.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances.
---	---

Obiltoxaximab SFL - obiltoxaximab - EMEA/H/C/005169/S/0004, Orphan SFL Pharmaceuticals Deutschland GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Liana Gross-Martirosyan	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances.
---	---

Obizur - susoctocog alfa - EMEA/H/C/002792/S/0044 Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.
---	--

on 24.02.2022.

**Vedrop - tocofersolan -
EMA/H/C/000920/S/0041**

Recordati Rare Diseases, Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Melinda Palfi

Positive Opinion adopted by consensus together with the CHMP assessment report.

The Marketing Authorisation remains under exceptional circumstances.

**Vyndaqel - tafamidis -
EMA/H/C/002294/S/0076, Orphan**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Tiphaine Vaillant
Request for Supplementary Information adopted on 24.02.2022.

Request for supplementary information adopted with a specific timetable.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

**Blitzima - rituximab -
EMA/H/C/004723/R/0049**

Celltrion Healthcare Hungary Kft., Duplicate, Duplicate of Truxima, Rapporteur: Sol Ruiz, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Anette Kirstine Stark

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

**Fampyra - fampridine -
EMA/H/C/002097/R/0050**

Biogen Netherlands B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Martina Weise, PRAC Rapporteur: Liana Gross-Martirosyan

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

**Imraldi - adalimumab -
EMA/H/C/004279/R/0050**

Samsung Bioepis NL B.V., Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Daniela Philadelphly, PRAC Rapporteur: Ulla Wändel Liminga

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

**Kalydeco - ivacaftor -
EMA/H/C/002494/R/0106, Orphan**

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Maria del Pilar Rayon

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that

Request for Supplementary Information adopted on 16.12.2021.	the renewal of the marketing authorisation can be granted with unlimited validity.
<p>Kevzara - sarilumab - EMEA/H/C/004254/R/0029</p> <p>sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Eva A. Segovia</p> <p>Request for Supplementary Information adopted on 16.12.2021.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Kyntheum - brodalumab - EMEA/H/C/003959/R/0019</p> <p>LEO Pharma A/S, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Eva A. Segovia</p> <p>Request for Supplementary Information adopted on 27.01.2022.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Mavenclad - cladribine - EMEA/H/C/004230/R/0022</p> <p>Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Rydapt - midostaurin - EMEA/H/C/004095/R/0023, Orphan</p> <p>Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva</p> <p>Request for Supplementary Information adopted on 24.02.2022.</p>	Request for supplementary information adopted with a specific timetable.
<p>Spherox - spheroids of human autologous matrix-associated chondrocytes - EMEA/H/C/002736/R/0024, ATMP</p> <p>CO.DON AG, Rapporteur: Lisbeth Barkholt, Co-Rapporteur: Heli Suila, CHMP Coordinators: Kristina Dunder and Outi Mäki-Ikola, PRAC Rapporteur: Brigitte Keller-Stanislawski</p> <p>Request for Supplementary Information adopted on 10.12.2021.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Tecentriq - atezolizumab - EMEA/H/C/004143/R/0069</p> <p>Roche Registration GmbH, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that</p>

Castro Lopes Silva	the renewal of the marketing authorisation can be granted with unlimited validity.
<p>Trumenba - meningococcal group b vaccine (recombinant, adsorbed) - EMEA/H/C/004051/R/0036</p> <p>Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Jean-Michel Dogné</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Vosevi - sofosbuvir / velpatasvir / voxilaprevir - EMEA/H/C/004350/R/0053</p> <p>Gilead Sciences Ireland UC, Rapporteur: Filip Josephson, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ana Sofia Diniz Martins</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Xermelo - telotristat ethyl - EMEA/H/C/003937/R/0032, Orphan</p> <p>Ipsen Pharma, Rapporteur: Martina Weise, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Adam Przybylkowski</p> <p>Request for Supplementary Information adopted on 24.02.2022.</p>	Request for supplementary information adopted with a specific timetable.
<p>B.2.3. Renewals of Conditional Marketing Authorisations</p>	
<p>Koselugo - selumetinib - EMEA/H/C/005244/R/0003, Orphan</p> <p>AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Annika Folin</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.</p> <p>The Marketing Authorisation remains conditional.</p>
<p>Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/R/0021, Orphan, ATMP</p> <p>Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, Co-Rapporteur: Egbert Flory, CHMP Coordinators: Johann Lodewijk Hillege and Jan-Mueller-Berghaus, PRAC Rapporteur: Ulla Wändel Liminga</p> <p>Request for Supplementary Information adopted on 18.02.2022.</p>	Request for supplementary information adopted with a specific timetable.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Post-authorisation safety studies

PRAC recommendations on PASS results adopted at the PRAC meeting held on 07-10 February 2022

HyQvia (CAP) – EMEA/H/C/PSR/S/0037 Adopted

(human normal immunoglobulin)
PRAC Rapporteur: Brigitte Keller-Stanislawski,
Scope: Results of study number 161302 (listed as a category 1 study in Annex II and the RMP): non-interventional post-authorisation study on long-term safety of Hyqvia in subjects treated with Hyqvia (human normal immunoglobulin)
PRAC recommendation to CHMP

Action: For adoption

Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on 07-10 February 2022
PRAC:

Signal of erythema multiforme Adopted

Xtandi – Enzalutamide

Rapporteur: Maria Concepcion Prieto Yerro,
Co-Rapporteur: Filip Josephson, PRAC
Rapporteur: Eva A. Segovia

PRAC recommendation on a variation

Action: For adoption

Signal of non-overt disseminated intravascular coagulation (DIC) Adopted

Gazyvaro – Obinutuzumab

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Annika Folin

PRAC recommendation on a variation

Action: For adoption

Signal of tumour lysis syndrome Adopted

Nexavar – Sorafenib

Rapporteur: Filip Josephson, Co-Rapporteur: Fatima Ventura, PRAC Rapporteur: Annika Folin

PRAC recommendation on a variation

Action: For adoption

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its February 2022 meeting:

EMA/H/C/PSUSA/0000476/202106

(cabazitaxel)

CAPS:

Cabazitaxel Accord (EMA/H/C/005178)

(cabazitaxel), Accord Healthcare S.L.U.,

Rapporteur: Hrefna Gudmundsdottir

Jevtana (EMA/H/C/002018) (cabazitaxel), sanofi-aventis groupe, Rapporteur: Alexandre

Moreau

NAPS:

NAPs - EU

PRAC Rapporteur: Tiphaine Vaillant,

"17/12/2019 To: 17/06/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisations for the medicinal products containing the above referred active substance, concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reactions nail disorder, gastrointestinal haemorrhage, ileus, gastritis, colitis, and gastrointestinal perforation, with appropriate frequencies. The Package leaflet is updated accordingly.

EMA/H/C/PSUSA/0001702/202106

(ibandronic acid, sodium ibandronate)

CAPS:

Bondronat (EMA/H/C/000101) (ibandronic

acid), Atnahs Pharma Netherlands B.V.,

Rapporteur: Thalia Marie Estrup Blicher

Bonviva (EMA/H/C/000501) (ibandronic acid),

Atnahs Pharma Netherlands B.V., Rapporteur:

Thalia Marie Estrup Blicher, PRAC Rapporteur:

Anette Kirstine Stark, "25/06/2018 To:

24/06/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product containing ibandronic acid (osteoporotic indication (Bonviva)), concerning the following change(s): Update of section 4.8 of the SmPC to add the ADR hypocalcaemia with a frequency uncommon. The Package leaflet is updated accordingly.

EMA/H/C/PSUSA/00009255/202107

(perampanel)

CAPS:

Fycompa (EMA/H/C/002434) (perampanel),

Eisai GmbH, Rapporteur: Alexandre Moreau,

PRAC Rapporteur: Tiphaine Vaillant,

"22/07/2020 To: 22/07/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction hallucination with a frequency "uncommon". The Package leaflet is updated accordingly.

EMA/H/C/PSUSA/00010379/202107

(nivolumab)

CAPS:

OPDIVO (EMA/H/C/003985) (nivolumab),

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended,

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte
Keller-Stanislawski, "03/07/2020 To:
03/07/2021"

recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):
Update of section 4.8 of the SmPC to move the PTs: "lymphopenia, leucopenia, neutropenia, thrombocytopenia and anaemia", from the SOC "Investigations" to the SOC "Blood and lymphatic system disorders", and to move the PTs: "hyperglycaemia, hypoglycaemia and weight decreased", from the SOC "Investigations" to the SOC "Metabolism and nutrition disorders". Update of section 2 of the PL to add the risk of diabetic ketoacidosis, including the symptoms.

EMA/H/C/PSUSA/00010712/202107
(neratinib)

CAPS:

Nerlynx (EMA/H/C/004030) (neratinib), Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Menno van der Elst, "16/07/2020 To: 16/07/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):
Update of section 4.8 of the SmPC to add the adverse reaction syncope with a frequency common. The Package leaflet is updated accordingly.

EMA/H/C/PSUSA/00010922/202107
(icosapent ethyl)

CAPS:

Vazkepa (EMA/H/C/005398) (icosapent ethyl), Amarin Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Menno van der Elst, "26/07/2020 To: 25/07/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):
Update of section 4.8 the SmPC to add pharyngeal swelling with a frequency not known. The Package leaflet (PL) already contains such information. An update of the PL is therefore not requested.

EMA/H/C/PSUSA/00010924/202107
(remimazolam)

CAPS:

Byfavo (EMA/H/C/005246) (remimazolam), PAION Netherlands B.V., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Rhea Fitzgerald, "22/01/2021 To: 22/07/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):
Update of section 4.8 of the SmPC to add the

adverse reaction anaphylactic reaction with a frequency not known. The Package leaflet is updated accordingly.

B.4. EPARs / WPARs

**Breyanzi - lisocabtagene maraleucel /
lisocabtagene maraleucel -
EMA/H/C/004731, Orphan, ATMP**

Bristol-Myers Squibb Pharma EEIG, treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**Dasatinib Accord - dasatinib -
EMA/H/C/005446**

Accord Healthcare S.L.U., treatment of leukaemia, Generic, Duplicate, Generic of Sprycel, Duplicate of Dasatinib Accordpharma, Generic application (Article 10(1) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**Dasatinib Accordpharma - dasatinib -
EMA/H/C/005317**

Accord Healthcare S.L.U., treatment of leukaemia, Generic, Generic of Sprycel, Generic application (Article 10(1) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-
((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-
3,3-dimethyl-2-(2,2,2-trifluoroacetamido)
butanoyl)-6,6-dimethyl-3-
azabicyclo[3.1.0]hexane-2-carboxamide /
ritonavir - EMA/H/C/005973**

Pfizer Europe MA EEIG, treatment of COVID-19, New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**Sondelbay - teriparatide -
EMA/H/C/005827**

Accord Healthcare S.L.U., treatment of osteoporosis, Similar biological application (Article 10(4) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

**Stimufend - pegfilgrastim -
EMA/H/C/004780**

Fresenius Kabi Deutschland GmbH, treatment of neutropenia, Similar biological application

For information only. Comments can be sent to the PL in case necessary.

(Article 10(4) of Directive No 2001/83/EC)

**Vildagliptin/Metformin hydrochloride
Accord Healthcare - vildagliptin /
metformin hydrochloride -
EMA/H/C/005738**

For information only. Comments can be sent to the PL in case necessary.

Accord Healthcare S.L.U., treatment of type 2 diabetes mellitus, Generic, Generic of Eucreas, Generic application (Article 10(1) of Directive No 2001/83/EC)

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

**Allymsys - bevacizumab -
EMA/H/C/005286/II/0007/G**

Mabxience Research SL, Rapporteur: Christian Gartner

Request for Supplementary Information adopted on 17.02.2022.

Request for supplementary information adopted with a specific timetable.

**Apidra - insulin glulisine -
EMA/H/C/000557/II/0088/G**

Sanofi-Aventis Deutschland GmbH, Rapporteur: Sinan B. Sarac

Request for Supplementary Information adopted on 03.02.2022.

Request for supplementary information adopted with a specific timetable.

**Azacitidine Accord - azacitidine -
EMA/H/C/005147/II/0009**

Accord Healthcare S.L.U., Generic, Generic of Vidaza, Rapporteur: Hrefna Gudmundsdottir
Opinion adopted on 17.02.2022.

Positive Opinion adopted by consensus on 17.02.2022.

**Bexsero - meningococcal group B vaccine
(recombinant, component, adsorbed) -
EMA/H/C/002333/II/0106**

GSK Vaccines S.r.l, Rapporteur: Kristina Dunder
Opinion adopted on 10.02.2022.

Positive Opinion adopted by consensus on 10.02.2022.

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0056/G**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson,

"C.I.11.b, (Type II)- To submit additional data to complete characterisation of the active substance and finished product, which are a condition to the Marketing Authorisation (Special Obligation SO1)

Positive Opinion adopted by consensus on 17.02.2022.

C.I.11.b, (Type II)- To submit additional data to enhance the control strategy, including the active substance and finished product specifications, which are a condition to the Marketing Authorisation (Special Obligation SO2)

"

Opinion adopted on 17.02.2022.

Request for Supplementary Information adopted on 16.12.2021, 14.10.2021.

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0092/G**

BioNTech Manufacturing GmbH, Rapporteur:
Filip Josephson
Opinion adopted on 03.02.2022.

Positive Opinion adopted by consensus on 03.02.2022.

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0108/G**

BioNTech Manufacturing GmbH, Rapporteur:
Filip Josephson
Opinion adopted on 10.02.2022.

Positive Opinion adopted by consensus on 10.02.2022.

**COVID-19 Vaccine Janssen - adenovirus
type 26 encoding the sars-cov-2 spike
glycoprotein - EMA/H/C/005737/II/0037**

Janssen-Cilag International N.V., Rapporteur:
Christophe Focke
Opinion adopted on 10.02.2022.

Positive Opinion adopted by consensus on 10.02.2022.

**Elonva - corifollitropin alfa -
EMA/H/C/001106/II/0062**

Organon N.V., Rapporteur: Paula Boudewina van Hennik
Opinion adopted on 24.02.2022.

Request for Supplementary Information adopted on 16.12.2021.

Positive Opinion adopted by consensus on 24.02.2022.

**Enbrel - etanercept -
EMA/H/C/000262/II/0243/G**

Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro
Request for Supplementary Information adopted on 03.02.2022, 02.09.2021.

Request for supplementary information adopted with a specific timetable.

**Fluad Tetra - influenza vaccine (surface
antigen, inactivated, adjuvanted) -
EMA/H/C/004993/II/0021**

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz
Opinion adopted on 24.02.2022.
Request for Supplementary Information adopted on 13.01.2022.

Positive Opinion adopted by consensus on 24.02.2022.

Flucelvax Tetra - influenza vaccine surface Positive Opinion adopted by consensus on

<p>antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0024 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz Opinion adopted on 17.02.2022.</p>	17.02.2022.
<p>Herzuma - trastuzumab - EMEA/H/C/002575/II/0038 Celltrion Healthcare Hungary Kft., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 03.02.2022. Request for Supplementary Information adopted on 20.05.2021.</p>	Positive Opinion adopted by consensus on 03.02.2022.
<p>Imfinzi - durvalumab - EMEA/H/C/004771/II/0036 AstraZeneca AB, Rapporteur: Sinan B. Sarac Opinion adopted on 17.02.2022. Request for Supplementary Information adopted on 09.12.2021.</p>	Positive Opinion adopted by consensus on 17.02.2022.
<p>Invokana - canagliflozin - EMEA/H/C/002649/II/0058 Janssen-Cilag International N.V., Rapporteur: Martina Weise Opinion adopted on 03.02.2022.</p>	Positive Opinion adopted by consensus on 03.02.2022.
<p>Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0019/G Bayer AG, Rapporteur: Thalia Marie Estrup Blicher Request for Supplementary Information adopted on 10.02.2022, 07.10.2021.</p>	Request for supplementary information adopted with a specific timetable.
<p>Lamzede - velmanase alfa - EMEA/H/C/003922/II/0023/G, Orphan Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 03.02.2022.</p>	Request for supplementary information adopted with a specific timetable.
<p>Lysodren - mitotane - EMEA/H/C/000521/II/0024 HRA Pharma Rare Diseases, Rapporteur: Blanca Garcia-Ochoa Opinion adopted on 24.02.2022. Request for Supplementary Information adopted on 13.01.2022, 02.09.2021.</p>	Positive Opinion adopted by consensus on 24.02.2022.
<p>Ogivri - trastuzumab - EMEA/H/C/004916/II/0040 Viatris Limited, Rapporteur: Karin Janssen van Doorn Request for Supplementary Information adopted</p>	Request for supplementary information adopted with a specific timetable.

on 17.02.2022.

**Olanzapine Apotex - olanzapine -
EMA/H/C/001178/II/0045**

Apotex Europe BV, Generic, Generic of Zyprexa,
Rapporteur: John Joseph Borg
Opinion adopted on 17.02.2022.
Request for Supplementary Information adopted
on 13.01.2022, 02.09.2021.

Positive Opinion adopted by consensus on
17.02.2022.

**Perjeta - pertuzumab -
EMA/H/C/002547/II/0063**

Roche Registration GmbH, Rapporteur: Sinan B.
Sarac
Request for Supplementary Information adopted
on 17.02.2022.

Request for supplementary information adopted
with a specific timetable.

**Polivy - polatuzumab vedotin -
EMA/H/C/004870/II/0014/G, Orphan**

Roche Registration GmbH, Rapporteur:
Alexandre Moreau
Request for Supplementary Information adopted
on 03.02.2022.

Request for supplementary information adopted
with a specific timetable.

**POTELIGEO - mogamulizumab -
EMA/H/C/004232/II/0013/G, Orphan**

Kyowa Kirin Holdings B.V., Rapporteur: Paula
Boudewina van Hennik
Opinion adopted on 17.02.2022.
Request for Supplementary Information adopted
on 13.01.2022.

Positive Opinion adopted by consensus on
17.02.2022.

**Rekovelte - follitropin delta -
EMA/H/C/003994/II/0030**

Ferring Pharmaceuticals A/S, Rapporteur: Jean-
Michel Race
Opinion adopted on 17.02.2022.
Request for Supplementary Information adopted
on 13.01.2022.

Positive Opinion adopted by consensus on
17.02.2022.

**Respreeza - human alpha1-proteinase
inhibitor - EMA/H/C/002739/II/0055/G**

CSL Behring GmbH, Rapporteur: Kristina
Dunder
Request for Supplementary Information adopted
on 17.02.2022.

Request for supplementary information adopted
with a specific timetable.

**Revestive - teduglutide -
EMA/H/C/002345/II/0055, Orphan**

Shire Pharmaceuticals Ireland Limited,
Rapporteur: Thalia Marie Estrup Blicher
Request for Supplementary Information adopted
on 17.02.2022, 16.12.2021.

Request for supplementary information adopted
with a specific timetable.

<p>Senshio - ospemifene - EMA/H/C/002780/II/0042/G</p> <p>Shionogi B.V., Rapporteur: Paula Boudewina van Hennik</p> <p>Request for Supplementary Information adopted on 10.02.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>SIBNAYAL - potassium citrate / potassium hydrogen carbonate - EMA/H/C/005407/II/0002/G</p> <p>Advicenne, Rapporteur: Johann Lodewijk Hillege</p> <p>Opinion adopted on 10.02.2022.</p>	<p>Positive Opinion adopted by consensus on 10.02.2022.</p>
<p>Skyrizi - risankizumab - EMA/H/C/004759/II/0019/G</p> <p>AbbVie Deutschland GmbH & Co. KG, Rapporteur: Peter Kiely</p> <p>Opinion adopted on 03.02.2022.</p>	<p>Positive Opinion adopted by consensus on 03.02.2022.</p>
<p>Soliris - eculizumab - EMA/H/C/000791/II/0118/G, Orphan</p> <p>Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa</p> <p>Opinion adopted on 03.02.2022.</p>	<p>Positive Opinion adopted by consensus on 03.02.2022.</p>
<p>Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005791/II/0038/G</p> <p>Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus</p> <p>Request for Supplementary Information adopted on 17.02.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005791/II/0046</p> <p>Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus</p> <p>Opinion adopted on 10.02.2022.</p>	<p>Positive Opinion adopted by consensus on 10.02.2022.</p>
<p>Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005791/II/0051/G</p> <p>Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus</p> <p>Opinion adopted on 24.02.2022.</p>	<p>Positive Opinion adopted by consensus on 24.02.2022.</p>
<p>Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005791/II/0052/G</p> <p>Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus</p> <p>Opinion adopted on 24.02.2022.</p>	<p>Positive Opinion adopted by consensus on 24.02.2022.</p>

<p>Supemtek - quadrivalent influenza vaccine (recombinant, prepared in cell culture) - EMEA/H/C/005159/II/0005/G</p> <p>Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus</p> <p>Opinion adopted on 10.02.2022.</p> <p>Request for Supplementary Information adopted on 16.12.2021.</p>	<p>Positive Opinion adopted by consensus on 10.02.2022.</p>
<p>Thyrogen - thyrotropin alfa - EMEA/H/C/000220/II/0109/G</p> <p>Genzyme Europe BV, Rapporteur: Peter Kiely</p> <p>Opinion adopted on 10.02.2022.</p> <p>Request for Supplementary Information adopted on 16.12.2021.</p>	<p>Positive Opinion adopted by consensus on 10.02.2022.</p>
<p>Trogarzo - ibalizumab - EMEA/H/C/004961/II/0016/G</p> <p>Theratechnologies Europe Limited, Rapporteur: Johann Lodewijk Hillege</p> <p>Request for Supplementary Information adopted on 17.02.2022, 25.11.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rDNA), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0093/G</p> <p>MCM Vaccine B.V., Rapporteur: Christophe Focke</p> <p>Opinion adopted on 10.02.2022.</p>	<p>Positive Opinion adopted by consensus on 10.02.2022.</p>
<p>VEYVONDI - vonicog alfa - EMEA/H/C/004454/II/0020</p> <p>Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus</p> <p>Opinion adopted on 24.02.2022.</p> <p>Request for Supplementary Information adopted on 16.12.2021.</p>	<p>Positive Opinion adopted by consensus on 24.02.2022.</p>
<p>Votrient - pazopanib - EMEA/H/C/001141/II/0071/G</p> <p>Novartis Europharm Limited, Rapporteur: Sinan B. Sarac</p> <p>Request for Supplementary Information adopted on 17.02.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Zavicefta - ceftazidime / avibactam - EMEA/H/C/004027/II/0027/G</p> <p>Pfizer Ireland Pharmaceuticals, Rapporteur: Ingrid Wang</p> <p>Opinion adopted on 24.02.2022.</p> <p>Request for Supplementary Information adopted</p>	<p>Positive Opinion adopted by consensus on 24.02.2022.</p>

on 13.01.2022, 02.12.2021, 28.10.2021,
09.09.2021.

**Zutectra - human hepatitis B
immunoglobulin -
EMA/H/C/001089/II/0050**

Biotest Pharma GmbH, Rapporteur: Jan Mueller-
Berghaus
Opinion adopted on 10.02.2022.
Request for Supplementary Information adopted
on 02.12.2021.

Positive Opinion adopted by consensus on
10.02.2022.

**WS2189
Advate-EMA/H/C/000520/WS2189/0113
ADYNOVI-
EMA/H/C/004195/WS2189/0026**

Takeda Manufacturing Austria AG, Lead
Rapporteur: Jan Mueller-Berghaus
Opinion adopted on 24.02.2022.
Request for Supplementary Information adopted
on 13.01.2022.

Positive Opinion adopted by consensus on
24.02.2022.

**WS2190
Lixiana-EMA/H/C/002629/WS2190/0036
Roteas-EMA/H/C/004339/WS2190/0023**

Daiichi Sankyo Europe GmbH, Lead Rapporteur:
Maria Concepcion Prieto Yerro
Request for Supplementary Information adopted
on 17.02.2022.

Request for supplementary information adopted
with a specific timetable.

**WS2199
Infanrix hexa-
EMA/H/C/000296/WS2199/0311**

GlaxoSmithkline Biologicals SA, Lead
Rapporteur: Christophe Focke
Opinion adopted on 17.02.2022.

Positive Opinion adopted by consensus on
17.02.2022.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

**AYVAKYT - avapritinib -
EMA/H/C/005208/II/0014, Orphan**

Blueprint Medicines (Netherlands) B.V.,
Rapporteur: Blanca Garcia-Ochoa, "Submission
of the final report from study BLU-285-1101
listed as a Specific Obligation in the Annex II of
the Product Information. This is an
interventional Phase 1 study, designed to
evaluate the safety, tolerability, PK,
pharmacodynamics, and preliminary
antineoplastic activity of avapritinib
administered orally in patients with unresectable
GIST or other relapsed or refractory solid

Request for supplementary information adopted
with a specific timetable.

tumours. The Annex II is updated accordingly.”
Request for Supplementary Information adopted
on 10.02.2022.

**Caprelsa - vandetanib -
EMA/H/C/002315/II/0052**

Genzyme Europe BV, Rapporteur: Alexandre Moreau, “Update of section 4.4 of the SmPC in order to amend an existing warning on renal failure based on safety signal evaluation report. In addition, the MAH took the opportunity to update the contact details for local representative in DE in the Package Leaflet.”
Request for Supplementary Information adopted on 24.02.2022.

Request for supplementary information adopted with a specific timetable.

**Cimzia - certolizumab pegol -
EMA/H/C/001037/II/0101**

UCB Pharma S.A., Rapporteur: Kristina Dunder, “C.I.4: Update of section 4.6 of the SmPC in order to update information on pregnancy based on non-interventional data from the UCB Global Safety Database on prospective Cimzia-exposed pregnancies with known outcomes; the Package Leaflet is updated accordingly.”
Request for Supplementary Information adopted on 17.02.2022, 11.11.2021.

Request for supplementary information adopted with a specific timetable.

**Cometriq - cabozantinib -
EMA/H/C/002640/II/0049, Orphan**

Ipsen Pharma, Rapporteur: Paula Boudewina van Hennik, “Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on hypertension and add hypertensive crisis to the list of adverse drug reactions (ADRs) with frequency not known based on literature review and post-marketing and clinical data. The Package Leaflet is updated accordingly.”
Request for Supplementary Information adopted on 03.02.2022.

Request for supplementary information adopted with a specific timetable.

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0093**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, “Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC of Comirnaty 30 microgram/dose and section 4.8 of the SmPC of Comirnaty 10 microgram/dose in order to update efficacy and safety information after booster dose and to change posology recommendations for booster use from “individuals 18 years of age and older” to

Positive Opinion adopted by consensus on 24.02.2022.

See 9.1

"individuals 16 years of age and older", based on interim results from study C4591031, this is a randomized, placebo-controlled, phase 3 booster efficacy study involving participants \geq 16 years of age who completed the primary series of BNT162b2 30 μ g in study C4591001, published literature data and post-marketing safety data. The Package Leaflet and Labelling are updated accordingly.

In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

Opinion adopted on 24.02.2022.

Request for Supplementary Information adopted on 27.01.2022.

COMIRNATY - tozinameran - EMEA/H/C/005735/II/0104

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update immunogenicity, safety and efficacy information regarding heterologous vaccination (both in the primary series and for booster vaccinations) based on published literature data; the Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

Request for Supplementary Information adopted on 24.02.2022.

Request for supplementary information adopted with a specific timetable.

See 9.1

COMIRNATY - tozinameran - EMEA/H/C/005735/II/0111

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC of Comirnaty 30 microgram/dose in order to change posology recommendations for booster use from "individuals 18 years of age and older" to "individuals 12 years of age and older", based on real world evidence collected by the Ministry of Health of Israel and published literature data. The Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

Opinion adopted on 24.02.2022.

Positive Opinion adopted by consensus on 24.02.2022.

See 9.1

Darzalex - daratumumab - EMEA/H/C/004077/II/0053, Orphan

Janssen-Cilag International N.V., Rapporteur:

Positive Opinion adopted by consensus on 24.02.2022.

Sinan B. Sarac, "C.I.4
Update of section 5.1 of the SmPC in order to
update PFS and OS (CCO 19/2/2021) data
based on interim results from study MMY3008;
This is a Phase 3, randomized, open-label,
active controlled, parallel-group, multicenter
study in adults with newly diagnosed MM not
eligible for ASCT comparing DRd vs Rd. The
Marketing authorisation holder (MAH) took the
opportunity to make minor formatting and
linguistic changes in the PI."
Opinion adopted on 24.02.2022.
Request for Supplementary Information adopted
on 07.10.2021, 02.09.2021.

**Edarbi - azilsartan medoxomil -
EMA/H/C/002293/II/0030/G**

Positive Opinion adopted by consensus on
24.02.2022.

Takeda Pharma A/S, Rapporteur: Johann
Lodewijk Hillege, "Group of variations:
· Type II C.I.4. - Update of SmPC sections 4.2,
4.8 and 5.1 with paediatric clinical data from
study AR14.001 (PIP study 8) following the
outcome of procedure
EMA/H/C/002293/P46/012.
· Type II C.I.4. - Update of SmPC section 5.2
with paediatric clinical data from study TAK-
491_109 (PIP study 7) following the outcome of
procedure EMA/H/C/002293/P46/011.
· Type II C.I.4. - Update of SmPC section 5.3
with data from juvenile animal toxicity studies.
· Type II C.I.4. - Update of SmPC section 4.5
with drug-drug interaction information from
clinical pharmacology studies TAK-491-013 and
TAK-563-004.
Furthermore, the MAH is taking the opportunity
to update the PI in line with the latest QRD
template version 10.2, update the local
representatives for Ireland, Slovenia and United
Kingdom in the Package Leaflet (PL) and update
minor editorial/typographical to Product
information."
Opinion adopted on 24.02.2022.
Request for Supplementary Information adopted
on 09.12.2021.

**Eylea - aflibercept -
EMA/H/C/002392/II/0073**

Positive Opinion adopted by consensus on
24.02.2022.

Bayer AG, Rapporteur: Alexandre Moreau,
"C.I.13 Other variations not specifically covered
elsewhere in this Annex which involve the
submission

of studies to the competent authority. PFS design change.”
Opinion adopted on 24.02.2022.
Request for Supplementary Information adopted on 16.12.2021, 16.09.2021.

**Eylea - aflibercept -
EMA/H/C/002392/II/0076**

Positive Opinion adopted by consensus on 17.02.2022.

Bayer AG, Rapporteur: Alexandre Moreau, “Submission of the final report from study AZURE, a randomised PAES in patients with neovascular (wet) AMD with the primary objective of comparing the standard regime of injections every 8 weeks with a reactive regimen based on visual and anatomic outcomes, based on a CHMP approved protocol.”

Opinion adopted on 17.02.2022.
Request for Supplementary Information adopted on 13.01.2022.

**Eylea - aflibercept -
EMA/H/C/002392/II/0078**

Positive Opinion adopted by consensus on 10.02.2022.

Bayer AG, Rapporteur: Alexandre Moreau, “Update of the PI in line with the latest QRD template version 10.2, text reduction, and correction of a typo.”

Opinion adopted on 10.02.2022.

**Fabrazyme - agalsidase beta -
EMA/H/C/000370/II/0123**

Request for supplementary information adopted with a specific timetable.

Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.2 and 6.6 of the SmPC in order to modify administration instructions based on pre-existing data from the clinical trials AGAL-01-002-98, AGAL-005-99, AGAL-008-00, AGAL-02503 and AGAL-016-01 that already serve as the basis for the currently approved SmPC. In addition, section 5.1 of the SmPC is updated in order to add further information on Fabry patients included in the clinical trials. The Package Leaflet is updated accordingly.”

Request for Supplementary Information adopted on 10.02.2022.

**Feraccru - ferric maltol -
EMA/H/C/002733/II/0033**

Request for supplementary information adopted with a specific timetable.

Norgine B.V., Rapporteur: Maria Concepcion Prieto Yerro, “to remove haemoglobin threshold from section 4.4 ‘Special warnings and precautions for use’ of summary of product

characteristics for Feraccru Capsules 30 mg, deleting the reference made that states "Feraccru is not recommended for use in patients with haemoglobin (Hb) <9.5 g/dl." Request for Supplementary Information adopted on 03.02.2022, 21.10.2021, 22.07.2021.

Fetcroja - cefiderocol -

EMA/H/C/004829/II/0006/G

Shionogi B.V., Rapporteur: Filip Josephson, "Submission of the final report from the in vitro RIS correlation study S-649266-PF-415-N (REC 003), to address CYP3A4 induction by cefiderocol.

In addition, the MAH submitted the final report of in vitro study S-649266-CPK-008-C to investigate the DDI between cefiderocol as a CYP3A4 inducer and Midazolam using physiologically-based pharmacokinetic model." Opinion adopted on 24.02.2022.

Request for Supplementary Information adopted on 13.01.2022, 11.11.2021.

Positive Opinion adopted by consensus on 24.02.2022.

Gardasil 9 - human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58]

(recombinant, adsorbed) -

EMA/H/C/003852/II/0053

MSD Vaccines, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update long-term effectiveness and immunogenicity data following the final results of the Gardasil 9 long-term follow-up (LTFU) study V503-002-20 listed as a category 3 study in the RMP. In addition, the applicant took the opportunity to make some minor editorial changes (spacings) and included the updated long-term follow-up data received for the qHPV vaccine following V501-167 extension study. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 17.02.2022.

Request for supplementary information adopted with a specific timetable.

Glivec - imatinib -

EMA/H/C/000406/II/0129

Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of section 4.8 of the SmPC in order to add pemphigus with frequency rare and osteonecrosis with frequency uncommon to the list of adverse drug reactions based on an analysis of pre-clinical data, scientific literature, clinical trial datasets, Novartis pharmacovigilance database, EVDAS

Positive Opinion adopted by consensus on 17.02.2022.

and other safety databases. The Package Leaflet is updated accordingly. The MAH is also taking the opportunity to align section 4 of the PL with the already approved ADR section of the SmPC as a number of ADRs is not reflected accurately.”

Opinion adopted on 17.02.2022.

**Imfinzi - durvalumab -
EMA/H/C/004771/II/0039/G**

AstraZeneca AB, Rapporteur: Sinan B. Sarac, “Update of section 4.2 of the SmPC in order to update the recommendation for dose modification for the adverse reaction myocarditis based on NCCN guideline recommendations (2021) and findings in a Global Patient Safety Database, and update of section 4.8 of the SmPC to further clarify the medical concept of the adverse reaction encephalitis, by revising the footnote of the ADR table for encephalitis”

Positive Opinion adopted by consensus on 24.02.2022.

**Imfinzi - durvalumab -
EMA/H/C/004771/II/0040**

AstraZeneca AB, Rapporteur: Sinan B. Sarac, “Update of section 5.1 of the SmPC in order to update efficacy data based on the results of the 5-year follow-up analysis of the PACIFIC study (a randomised, double blind, placebo controlled, multicentre study in patients with locally advanced, unresectable NSCLC). In addition, the MAH took the opportunity to include analyses of the exploratory endpoints to meet the commitment (recommendation) to submit exploratory analyses from the PACIFIC study.”
Opinion adopted on 17.02.2022.

Positive Opinion adopted by consensus on 17.02.2022.

**Jardiance - empagliflozin -
EMA/H/C/002677/II/0062/G**

Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, “Update of section 5.1 of the SmPC with the results of clinical study EMPULSE (1245-0204), a multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initiated in patients hospitalised for acUte heart faiLure (de novo or decompensated chronic HF) who have been StabilisEd (EMPULSE).
In addition, the MAH took the opportunity to implement editorial changes in the SmPC.”

Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 10.02.2022.

**Keytruda - pembrolizumab -
EMA/H/C/003820/II/0114**

Merck Sharp & Dohme B.V., Rapporteur:
Armando Genazzani, "Update of sections 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-087 listed as an imposed PAES in the Annex II; this is a multicentre, single-arm, multi-cohort, non-randomized Phase 2 study of IV pembrolizumab in participants with relapsed or refractory classical Hodgkin lymphoma (cHL)."

Opinion adopted on 17.02.2022.

Request for Supplementary Information adopted on 18.11.2021.

Positive Opinion adopted by consensus on 17.02.2022.

**Kovaltry - octocog alfa -
EMA/H/C/003825/II/0038**

Bayer AG, Rapporteur: Kristina Dunder, PRAC
Rapporteur: Brigitte Keller-Stanislawski,
"Update of the SmPC sections 4.8 and 5.1 to include data from the LEOPOLD Kids Part B (previously submitted as Art 46; an addendum on biomarker data is included in this submission) and extension study results included as part of this submission. In addition, an editorial revision in section 4.2 and a clarification in section 6.5 of the SmPC are proposed. Section 4 of the Package is updated accordingly. A correction of a typo in the Greek product information is also included. The Risk Management Plan for Kovaltry is updated using Revision 2.0.1 of the template format."

Request for Supplementary Information adopted on 10.02.2022, 02.12.2021.

Request for supplementary information adopted with a specific timetable.

**Kyprolis - carfilzomib -
EMA/H/C/003790/II/0051/G, Orphan**

Amgen Europe B.V., Rapporteur: Blanca Garcia-Ochoa, "A.6 The ATC code of the product is updated.

C.I.4, Update of section 4.2 of the SmPC in order to modify administration instructions of daratumumab when Kyprolis is dosed in combination with daratumumab and dexamethasone, based on results from efficacy and safety studies MMY2040 (ongoing phase 2), MMY1001 (completed phase 1b) and CANDOR (ongoing phase 3)."

Positive Opinion adopted by consensus on 24.02.2022.

Opinion adopted on 24.02.2022.
Request for Supplementary Information adopted
on 11.11.2021, 22.07.2021.

**MenQuadfi - meningococcal group a, c,
w135 and y conjugate vaccine -
EMA/H/C/005084/II/0013**

Positive Opinion adopted by consensus on
17.02.2022.

Sanofi Pasteur, Rapporteur: Andrea Laslop,
"Update of section 5.1 of the SmPC in order to
add data on the immunogenicity of serogroup C
based on the final results from study
MEQ00065; this is a study to compare the
immunogenicity and safety of serogroup C of a
single dose of Menquadfi to Nimenrix or NeisVac
in meningococcal naïve toddlers 12-23 months
of age."

Opinion adopted on 17.02.2022.

**Obizur - susoctocog alfa -
EMA/H/C/002792/II/0042**

Positive Opinion adopted by consensus on
24.02.2022.

Baxalta Innovations GmbH, Rapporteur: Andrea
Laslop, "Submission of the final report from
OBIZUR study 241502. This is a Phase 3,
multicenter, single-arm, open-label study of the
efficacy and safety of B-Domain deleted
recombinant porcine factor VIII (BAX 802) in
subjects with congenital hemophilia A with
factor VIII inhibitors undergoing surgical or
other invasive procedures. Changes to the
Product Information were implemented at the
request of the CHMP, in particular a
contraindication was added for Congenital
Haemophilia A with Inhibitors. In addition,
minor template changes were made to the
Product Information."

Opinion adopted on 24.02.2022.

Request for Supplementary Information adopted
on 16.12.2021.

**Ocaliva - obeticholic acid -
EMA/H/C/004093/II/0030, Orphan**

Request for supplementary information adopted
with a specific timetable.

Intercept Pharma International Limited,
Rapporteur: Blanca Garcia-Ochoa, "Update of
section 4.3 of the SmPC in order to include
contraindication in patients with decompensated
cirrhosis (e.g., Child-Pugh Class B or C) or a
prior decompensation event based on the MAH's
conclusion that it will not be feasible to establish
the safety and efficacy of Ocaliva in these
patients from either of the ongoing studies 747-
302 and 747-401 listed as Specific Obligations
in Annex II. Consequently, dosing instructions

for patients with CP-B and CP-C cirrhosis are no longer applicable and section 4.2 has been updated accordingly.

In addition, section 4.4 of the SmPC to include a new warning on monitoring and management of patients for possible progression of PBC and other hepatic adverse reactions.

The MAH has also taken the opportunity to remove the outdated term "primary biliary cirrhosis" from section 4.1 and to make editorial changes to sections 4.8, 4.9, 5.1 and Annex IIE to improve clarity and correct typographical errors. The Package Leaflet is updated accordingly.

Furthermore, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2"

Request for Supplementary Information adopted on 24.02.2022, 16.12.2021, 16.09.2021.

**Repatha - evolocumab -
EMA/H/C/003766/II/0057**

Positive Opinion adopted by consensus on 10.02.2022.

Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC based on the final study report from study 20120124 (HAUSER-OLE); an open-label, single-arm, multicentre study to evaluate the safety, tolerability and efficacy of evolocumab for low-density lipoprotein (LDL-C) Reduction, as add-on to diet and lipid-lowering therapy, in paediatric subjects from 10 to 17 years of age with heterozygous familial hypercholesterolemia (heFH) or homozygous familial hypercholesterolemia (HoFH) HAUSER-OLE (final analysis). The provision of the final study report addresses the requirements of Article 46 of the Paediatric Regulation."

Opinion adopted on 10.02.2022.

**Repatha - evolocumab -
EMA/H/C/003766/II/0058**

Request for supplementary information adopted with a specific timetable.

Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, "C.I.4 Update to section 5.1 of the SmPC following the results of interventional study 20160184.

It was a double-blind, placebo-controlled, randomised study evaluating the effect of evolocumab on coronary atherosclerotic plaques as assessed by optical coherence tomography (OCT) following 50 weeks of treatment in subjects with non-ST-elevation acute coronary

syndrome (NSTE-ACS) who take maximally tolerated statin therapy.”

Request for Supplementary Information adopted on 17.02.2022.

Roclanda - latanoprost / netarsudil - EMEA/H/C/005107/II/0002

Santen Oy, Rapporteur: Jayne Crowe, “C.I.4, Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study PG324-CS303; this is a prospective, double-masked, randomized, multicentre, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of Roclanda compared to bimatoprost + timolol in subjects with elevated intraocular pressure that was insufficiently controlled and/or deemed to be in need of combination IOP-lowering therapy. The Package Leaflet is updated accordingly.”

Request for Supplementary Information adopted on 24.02.2022.

Request for supplementary information adopted with a specific timetable.

Ronapreve - casirivimab / imdevimab - EMEA/H/C/005814/II/0001

Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.1, 4.4 and 5.1 of the SmPC in order to update information on the in vitro neutralisation activity of casirivimab/imdevimab against the SARS-CoV-2 B.1.1.529 (Omicron) variant.”

Request for Supplementary Information adopted on 10.02.2022.

Request for supplementary information adopted with a specific timetable.

Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0042

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.2 and 5.1 of the SmPC in order to include information on heterologous boosting using a 50 ug dose of Spikevax to boost subjects that have previously completed a primary vaccination series with any authorised COVID-19 vaccine, and to shorten the duration of the interval between the primary series and the booster dose to 3 months, based on data from the DMID study 21-0012, a Phase 1/2 heterologous SARS-CoV-2 vaccine dosing (mRNA-1273 booster) study of the various vaccines authorised in the US under Emergency Use Authorisation in participants ≥ 18 years old (NCT04889209). In addition, the MAH took the

Positive Opinion adopted by consensus on 24.02.2022.

See 9.1

opportunity to implement the WHO-approved INN 'elasomeran' and make minor editorial changes/corrections throughout the product information. The Annex A, the Labelling and the Package Leaflet are amended accordingly." Request for Supplementary Information adopted on 27.01.2022, 16.12.2021.

Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0047

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "Update of section 5.1 of the SmPC in order to introduce data on the immunogenicity of Spikevax against the B.1.617.2 (Delta) variant in adults and children, based on cross-neutralisation data from studies mRNA-1273-P301 (an ongoing Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older - NCT04470427), mRNA-1273-P201B (Part B of an ongoing Phase 2a, Randomized, Observer-Blind, Placebo-Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older - NCT04405076), and mRNA-1273-P204 (an ongoing Phase 2/3, 2-part, open-label, dose-escalation, age de-escalation and subsequent randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 in healthy children - NCT04796896)." Opinion adopted on 24.02.2022.

Positive Opinion adopted by consensus on 24.02.2022.

See 9.1

Spravato - esketamine - EMEA/H/C/004535/II/0012

Janssen-Cilag International N.V., Rapporteur: Martina Weise, "Update to the SmPC section 4.2 and section 5.1, based on the findings in Chinese subjects from a recently completed efficacy Phase 3 study in adults with treatment-resistant depression." Request for Supplementary Information adopted on 10.02.2022.

Request for supplementary information adopted with a specific timetable.

Trumenba - meningococcal group b vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0037

Request for supplementary information adopted with a specific timetable.

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.8 and 5.1 of the SmPC in order to include immunopersistence and booster data based on final results from study B1971035 listed as a part of the paediatric investigation plan; this is a phase 2, randomized, controlled, observer-blinded study conducted to describe the immunogenicity, safety, and tolerability of Bivalent rLP2086 when administered to healthy toddlers aged 12 to <18 months or 18 to <24 months, and the safety and immunogenicity of a booster dose of Bivalent rLP2086."
Request for Supplementary Information adopted on 17.02.2022.

**Tysabri - natalizumab -
EMA/H/C/000603/II/0131**

Positive Opinion adopted by consensus on 10.02.2022.

Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, "C.I.4 Type II Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic information based on final results from study 101MS329 (NOVA) part 1. This is a randomized, controlled phase 3b study of efficacy, safety and tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab in subjects with Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment."

Opinion adopted on 10.02.2022.

**Vaborem - meropenem / vaborbactam -
EMA/H/C/004669/II/0010/G**

Request for supplementary information adopted with a specific timetable.

Menarini International Operations Luxembourg S.A., Rapporteur: Filip Josephson, "A grouped application including 8 type II variations (C.I.4) and 1 type II variation (C.I.13):

Update of section 4.5 of the SmPC based on the results of a series of non-clinical drug-drug interaction studies undertaken with vaborbactam or meropenem. The Package Leaflet has been updated accordingly. In addition, the MAH has submitted non-clinical data on the phototoxicity potential of meropenem from a 3T3 neutral red uptake phototoxicity test."

Request for Supplementary Information adopted on 17.02.2022, 25.11.2021, 11.03.2021.

Veklury - remdesivir -

Positive Opinion adopted by consensus on

EMA/H/C/005622/II/0026/G

03.02.2022.

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Grouped variation updating sections 4.6, 5.2 and 5.3 of the SmPC in order to update information in these sections considering new nonclinical data requested at the time of the initial conditional marketing application (EMA/H/C/005622)."

Opinion adopted on 03.02.2022.

Request for Supplementary Information adopted on 02.12.2021.

**Viread - tenofovir disoproxil -
EMA/H/C/000419/II/0204**Positive Opinion adopted by consensus on
24.02.2022.

Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Nathalie Gault, "Submission of final study report for study GS-US-174-0144, listed as category 3 study in the RMP for Viread. This is a randomized, double-blind evaluation of the antiviral efficacy, safety and tolerability of Tenofovir disoproxil fumarate. This application fulfils the Article 46 commitment to provide the final week 192 study results for clinical measure 'study 5' (study GS_US_174-0144) listed in the PIP. Section 5.1 of the SmPC is being amended accordingly. Additionally, the risk minimisation measures for paediatrics are being removed from the RMP and Annex II of the PI. The Package Leaflet has been updated accordingly. The MAH took the opportunity to implement minor linguistic amendments throughout the PI. In addition, the expression of lactose content in Annex I for the tablets was changed, to refer to lactose base (not as monohydrate), in line with current practice. The RMP version 25.1 has been submitted."

Opinion adopted on 24.02.2022.

Request for Supplementary Information adopted on 11.11.2021, 08.07.2021.

WS2154**CONTROLOC Control-****EMA/H/C/001097/WS2154/0038****PANTOLOC Control (SRD)-****EMA/H/C/001100/WS2154/0043****PANTOZOL Control-****EMA/H/C/001013/WS2154/0040****SOMAC Control-****EMA/H/C/001098/WS2154/0039**

Request for supplementary information adopted
with a specific timetable.

Takeda GmbH, Lead Rapporteur: Romaldas Mačiulaitis, "C.1.4 - Update of section 4.8 of the SmPC to update the existing term "Interstitial nephritis" to "Tubulointerstitial nephritis (TIN)" in line with the updated Company Core Data Sheet.

In addition, section 4.4 of the SmPC for centralised authorised products is updated with the excipient warning for sodium as per EMA guideline EMA/CHMP/302620/2017/EN Rev. 1. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the PL and to bring the PI in line with the last QRD template (version 10.1). This procedure also includes NAPs as listed in Annex B."

Request for Supplementary Information adopted on 24.02.2022, 09.12.2021.

WS2183

Infanrix hexa-

EMA/H/C/000296/WS2183/0310

GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke, "Update of sections 2 and 4.3 of the SmPC for Infanrix Hexa in order to remove the residue formaldehyde. The PL is updated accordingly. Moreover, these sections are also been updated for the removal of some residues currently mentioned in the Product Information (PI) of some of GSK's DTPa/dTpa combined vaccines (NAPs). In addition, the MAH took the opportunity to align the PI to the Annex to the European Commission guideline on "Excipients in the labelling and package leaflet of medicinal product for human use" (sections 2, 4.4 and 6.1 of the SmPC). The MAH also took the opportunity to introduce some additional minor changes to the PI and to update the list of local representatives in the Package Leaflet."

Request for Supplementary Information adopted on 03.02.2022.

Request for supplementary information adopted with a specific timetable.

B.5.3. CHMP-PRAC assessed procedures

**Alunbrig - brigatinib / brigatinib -
EMA/H/C/004248/II/0037**

Takeda Pharma A/S, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of section 5.1 of the SmPC in order to update efficacy

Positive Opinion adopted by consensus on 17.02.2022.

information based on final results from study AP26113-13-301 listed as a PAES in the Annex II; this is a randomised, open-label, multicentre phase III study comparing brigatinib versus crizotinib in patients with advanced ALK-positive NSCLC who have not previously received ALK-directed therapy; The RMP version 6.0 has also been submitted.”

Opinion adopted on 17.02.2022.

Request for Supplementary Information adopted on 13.01.2022, 30.09.2021.

**Erleada - apalutamide -
EMA/H/C/004452/II/0017**

Positive Opinion adopted by consensus on 10.02.2022.

Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Tiphaine Vaillant, “Update of section 5.3 of the SmPC in order to update non-clinical

information based on final results from study TOX11338 listed as PAM (EMA/H/C/004452/MEA/006); this is a 2-year carcinogenicity study of JNJ-56021927-AAA by oral gavage in rats; The RMP version 4.1 has also been submitted. In addition, the MAH has taken this opportunity to include general information in the RMP regarding study TITAN (PCR3002).”

Opinion adopted on 10.02.2022.

Request for Supplementary Information adopted on 02.12.2021.

**Halaven - eribulin -
EMA/H/C/002084/II/0060**

Positive Opinion adopted by consensus on 10.02.2022.

Eisai GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic information based on results from clinical studies E7389-A001-113, E7389-G000-223 and E7389-G000-213 in the paediatric population (6 months to <18 years); the Package Leaflet is updated accordingly. The RMP version 6.0 has also been submitted.”

Opinion adopted on 10.02.2022.

**IBRANCE - palbociclib -
EMA/H/C/003853/II/0037**

Request for supplementary information adopted with a specific timetable.

Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, PRAC Rapporteur: Anette Kirstine Stark, “Submission of an updated RMP version 1.8 in order to remove the Important Potential Risk Hyperglycaemia based on the study results

from A5481027, a PAM adopted at the initial MA; this is a multicentre, randomized, double-blind, phase 3 study of palbociclib plus letrozole versus placebo plus letrozole for the treatment of previously untreated Asian postmenopausal women with ER-positive, HER2-negative advanced breast cancer to evaluate the effect of palbociclib on hyperglycaemia - category 3 study.”

Request for Supplementary Information adopted on 10.02.2022.

Kaftrio - ivacaftor / tezacaftor / elexacaftor -

EMA/H/C/005269/II/0017/G, Orphan

Vertex Pharmaceuticals (Ireland) Limited,
Rapporteur: Johann Lodewijk Hillege, PRAC
Rapporteur: Martin Huber, “C.I.4

Update of section 5.3 of the SmPC in order to update the non-clinical information based on final results from a 2-year oral carcinogenicity study in rats (VX-445-TX-015) evaluating the carcinogenic potential of up to 10 mg/kg/day of elexacaftor. An updated RMP (version 6.0) has also been submitted to include the completion of the 2-year carcinogenicity study in rats as well as to update the post-market pregnancy safety information collection form following EMA/H/C/WS2048.

C.I.13

To submit the final report of Tezacaftor Juvenile Toxicity study (VX-661-TX-038).”

Request for Supplementary Information adopted on 10.02.2022.

Request for supplementary information adopted with a specific timetable.

Lojuxta - lomitapide -

EMA/H/C/002578/II/0046

Amryt Pharmaceuticals DAC, Rapporteur:
Johann Lodewijk Hillege, PRAC Rapporteur:
Menno van der Elst, “To propose an alternative study (LILITH) to the currently agreed protocol for the CAPTURE study. The new study proposes an evaluation of the effect of lomitapide treatment on major adverse cardiovascular events (MACE) in patients with homozygous familial hypercholesterolemia. Consequential submission of an updated RMP (version 6.9) and Annex IID of the Product Information. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2”

Positive Opinion adopted by consensus on 24.02.2022.

Opinion adopted on 24.02.2022.
Request for Supplementary Information adopted
on 16.12.2021, 22.07.2021, 09.04.2021.

**Natpar - parathyroid hormone -
EMA/H/C/003861/II/0029, Orphan**

Takeda Pharmaceuticals International AG,
Rapporteur: Karin Janssen van Doorn, PRAC
Rapporteur: Rhea Fitzgerald, "Submission of the
final results of study SHP634-101: An Open-
Label, Randomized, Crossover Study to Assess
the Pharmacokinetic and Pharmacodynamic
Profiles of Once-Daily and Twice-Daily Dose
Regimens of recombinant human Parathyroid
Hormone (rhPTH[1-84]) Administered
Subcutaneously to Subjects with
Hypoparathyroidism. Further clinical evaluation
of an alternative dosing regimen is no longer
warranted, as outlined in the current specific
obligation (study SHP634-403). The conditional
marketing authorisation can therefore be
converted into a standard marketing
authorisation (no longer subject to a specific
obligation) valid for 5 years."

Opinion adopted on 24.02.2022.
Request for Supplementary Information adopted
on 11.11.2021, 24.06.2021.

Negative Opinion adopted by consensus on
24.02.2022.

**Nerlynx - neratinib -
EMA/H/C/004030/II/0027**

Pierre Fabre Medicament, Rapporteur: Bruno
Sepodes, PRAC Rapporteur: Menno van der Elst,
"Update of section 5.1 of the SmPC in order to
update the pharmacokinetic information with
descriptive diarrhoea characteristics based on
final results from study PUMA-NER-6201
(CONTROL), listed as a category 3 study in the
RMP; this is an Open-Label Study to
Characterize the Incidence and Severity of
Diarrhea in Patients with Early Stage HER2+
Breast Cancer Treated with Neratinib and
Loperamide. The RMP version 2.1 has also been
submitted. In addition, the MAH took the
opportunity to introduce editorial updates in
section 4.2 of the SmPC."

Request for Supplementary Information adopted
on 10.02.2022.

Request for supplementary information adopted
with a specific timetable.

**Ondexxya - andexanet alfa -
EMA/H/C/004108/II/0022/G**

Alexion Europe SAS, Rapporteur: Jan Mueller-
Berghaus, PRAC Rapporteur: Menno van der

Request for supplementary information adopted
with a specific timetable.

Elst, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based the final study report from study 14-505 (ANNEXA-4). This is a Prospective, open-label study of andexanet alfa in patients receiving a factor Xa inhibitor who have acute major bleeding to confirm safety and efficacy in patients with acute major bleeds. The provision of this study report fulfils Specific Obligation 001, and as a consequence it has been deleted in the Annex II. The package leaflet was updated accordingly, and the applicant took the opportunity to implement editorial changes in the Annexes. The revised RMP version 2.4 has also been submitted.

Change to the summary of pharmacovigilance system due to change in QPPV."

Request for Supplementary Information adopted on 24.02.2022, 16.12.2021, 16.09.2021.

Oxlumo - lumasiran -

EMA/H/C/005040/II/0008, Orphan

Alnylam Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to clarify administration instructions, remove an existing warning on metabolic acidosis in patients with severe or end stage renal impairment, update the description of adverse reactions injection site reactions, abdominal pain and immunogenicity, update efficacy, pharmacokinetic information based on interim results from a category 3 study in the RMP ILLUMINATE-C (ALN-GO1-005): A single arm study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) and, in addition, based on available long-term efficacy and safety data from ongoing phase 3 studies ALN-GO1-003 in PH1 patients >6 years old and ALN-GO1-004 in PH1 patients <6 years old, and open-label extension study ALN-GO1-002. The Package Leaflet is updated accordingly. The RMP version 1.1 has also been submitted."

Request for Supplementary Information adopted on 24.02.2022.

Request for supplementary information adopted with a specific timetable.

Prolia - denosumab -

EMA/H/C/001120/II/0093

Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga,

Request for supplementary information adopted with a specific timetable.

“Update of sections 4.2 and 4.4 of the SmPC in order to change the posology recommendation for paediatric population and add a new warning on hypercalcaemia in paediatric patients with osteogenesis imperfecta following an urgent safety measure regarding the risk of hypercalcaemia reported very commonly in ongoing clinical trials in paediatric patients with osteogenesis imperfecta (OI) treated with denosumab; the Package Leaflet is updated accordingly. The RMP version 29.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to implement minor editorial changes in the Labelling.”

Request for Supplementary Information adopted on 24.02.2022.

**Reagila - cariprazine -
EMA/H/C/002770/II/0023**

Positive Opinion adopted by consensus on 10.02.2022.

Gedeon Richter Plc., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ana Sofia Diniz Martins, “Update of sections 4.4, 4.5, 4.6 and 5.2 of the SmPC in order to update pharmacokinetic information based on final results from RGH-188-302 (CAROLA) study listed as a category 3 study in the RMP; this is an open-label, single-arm, fixed-sequence, phase 1 trial in female schizophrenia patients to investigate the effect of multiple-dose administration of cariprazine on the pharmacokinetics of a combined oral contraceptive containing ethinylestradiol and levonorgestrel; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to implement minor editorial changes in sections 4.8 and 5.3 of the SmPC and in the PL.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).”

Opinion adopted on 10.02.2022.

Request for Supplementary Information adopted on 28.10.2021.

**TOOKAD - padeliporfin -
EMA/H/C/004182/II/0015**

Positive Opinion adopted by consensus on 10.02.2022.

STEBA Biotech S.A, Rapporteur: Bruno Sepodes,

PRAC Rapporteur: Maia Uusküla, "Submission of the Clinical Study Report for category 1 study: Post-authorisation efficacy study (PAES) CLIN1001 PCM301FU5, A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD Soluble for Localised Prostate Cancer compared to Active Surveillance. The Annex II has been updated to remove reference to this study. The RMP version 8.0 is approved." Opinion adopted on 10.02.2022.
Request for Supplementary Information adopted on 30.09.2021.

XOSPATA - gilteritinib -

EMA/H/C/004752/II/0007, Orphan

Astellas Pharma Europe B.V., Rapporteur: Ingrid Wang, PRAC Rapporteur: Martin Huber, "Submission of the report of an integrated analysis to demonstrate the safety of long-term treatment with gilteritinib when all patients enrolled in studies 2215-CL-0101, 2215-CL-0102 and 2215-CL-0301 have completed at least 3 years of treatment with gilteritinib or have withdrawn prior to completing at least 3 years of treatment.

The studies refer to: 1) study 2215-CL-0101: a phase 1/2 open-label, dose escalation study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASP2215 (gilteritinib) in patients with relapsed or refractory acute myeloid leukaemia (AML); 2) study 2215-CL-0102: a phase 1 open-label, dose escalation study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASP2215 in Japanese patients with relapsed or refractory AML; 3) study 2215-CL-0301: a phase 3 open-label, multicentre, randomized study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory AML with FMS-like tyrosine kinase 3 (FLT3) mutation.

The RMP (version 2.0) is updated in order to address the missing information regarding the safety of Xospata (gilteritinib)."

Request for Supplementary Information adopted on 10.02.2022.

Request for supplementary information adopted with a specific timetable.

Zejula - niraparib -

EMA/H/C/004249/II/0033, Orphan

GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, PRAC Rapporteur: Jan Neuhauser,

Request for supplementary information adopted with a specific timetable.

“Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning and add MDS/AML to the list of adverse drug reactions (ADRs) with frequency common and update of section 5.1 based on final results from NOVA study (213356); this is a Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer. In addition, the MAH also took this opportunity to update sections 4.4 and 4.6 to update information on contraception based on EMA and CTFG recommendations. The Package Leaflet is updated accordingly. The RMP version 6 has also been submitted.”

Request for Supplementary Information adopted on 10.02.2022.

WS2153

OPDIVO-

EMA/H/C/003985/WS2153/0111

Yervoy-EMA/H/C/002213/WS2153/0093

Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Paula Boudewina van Hennik, Lead PRAC Rapporteur: Brigitte Keller-Stanislowski, “Update of sections 4.2 and 6.6 of the SmPC to change the infusion time for ipilimumab when used as monotherapy or in combination with nivolumab in the melanoma indications; the Package Leaflet for Yervoy is updated accordingly. The RMP versions 35.0 for Yervoy and 26.2 for Opdivo have also been submitted. In addition, an administrative update in Annex II of Yervoy is introduced.”

Opinion adopted on 24.02.2022.

Request for Supplementary Information adopted on 11.11.2021.

Positive Opinion adopted by consensus on 24.02.2022.

B.5.4. PRAC assessed procedures

PRAC Led

Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMA/H/C/000721/II/0114

GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, “Submission of the final report from study EPI-HPV-048 listed as a category 3 study in the RMP. This surveillance study is part of the two-phase national HPV surveillance programme that was initiated in the

Request for supplementary information adopted with a specific timetable.

UK by the Health Protection Agency in order to evaluate the impact of HPV vaccination on HPV type replacement. The study aimed to assess the prevalence of type-specific HPV deoxyribonucleic acid (DNA) in young women in England since HPV immunisation using Cervarix was introduced. In addition, the MAH has included for information the protocol of study EPI-HPV-099 to address the safety concern "Impact and effectiveness against anal lesions and cancer. The RMP version 25 has also been submitted."

Request for Supplementary Information adopted on 10.02.2022.

PRAC Led

**Enbrel - etanercept -
EMA/H/C/000262/II/0244**

Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.13: Submission of the final report from study B1801310 (BIKER), listed as a category 3 study in the RMP. This is an observational Post-Authorisation Safety Study (PASS) of Etanercept and Methotrexate in the treatment of Juvenile Idiopathic Arthritis (JIA) using data obtained from participants in the German Biologics JIA Registry (BIKER) to monitor long-term safety and effectiveness of etanercept in the treatment of JIA in regular clinical practice."

Request for Supplementary Information adopted on 10.02.2022, 02.09.2021.

Request for supplementary information adopted with a specific timetable.

PRAC Led

**Mysimba - naltrexone hydrochloride /
bupropion hydrochloride -
EMA/H/C/003687/II/0054**

Orexigen Therapeutics Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of the final report from study NB-542 listed as a category 3 PASS in the RMP. This is a cross-sectional survey aimed to evaluate the effectiveness of the Mysimba Physician Prescribing Checklist (PPC) among physicians in the EU. The RMP version 12.6 has also been submitted."

Request for Supplementary Information adopted on 10.02.2022.

Request for supplementary information adopted with a specific timetable.

PRAC Led

Nplate - romiplostim -

EMA/H/C/000942/II/0083

Amgen Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Submission of the final report from study 20070797 listed as a category 3 study in the RMP. This is an observational study assessing the long-term safety of romiplostim treatment in real-life clinical practice in three Nordic countries. The RMP version 21.0 has also been submitted." Request for Supplementary Information adopted on 10.02.2022.

Request for supplementary information adopted with a specific timetable.

PRAC Led

Opsumit - macitentan -

EMA/H/C/002697/II/0042, Orphan

Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Update of the Risk management plan to v12.2 and consequential update of the Annex II and the patient alert card in the labelling based on the outcome of the PRAC assessment of EMA/H/C/PSUSA/00010115/202010:
- The controlled distribution system and Prescriber Kit (SmPC, prescribing check list and HCP brochure) is being removed as additional risk minimisation measures (aRMM) in the RMP and in the product information Annex II.D. Only the patient card is remaining as an aRMM.
- Off-label use is being removed from the list of safety concerns.
- "Elderly patients aged over 75 years", "Patients with moderate to severe hepatic impairment" and "Patients with severe renal impairment and/ or undergoing dialysis" are being removed as missing information.
- The MAH has also taken the opportunity to include in the RMP Annex 4, the updated Specific Follow-up Questionnaires Forms (pregnancies, menstrual disorders and ovarian cysts) due to revision of internal company template."
Opinion adopted on 10.02.2022.
Request for Supplementary Information adopted on 28.10.2021.

Positive Opinion adopted by consensus on 10.02.2022.

<p>PRAC Led</p> <p>Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0022</p> <p>Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Hans Christian Siersted, PRAC-CHMP liaison: Sinan B. Sarac, "Submission of an updated RMP version 2.3 to include clinical safety data from study mRNA-1273 P203 (NCT04649151), a Phase 2/3, randomised, observer-blind, placebo-controlled study evaluating the safety, reactogenicity, and effectiveness of the mRNA-1273 vaccine in healthy adolescents aged ≥ 12 to < 18 years."</p> <p>Opinion adopted on 10.02.2022.</p> <p>Request for Supplementary Information adopted on 02.12.2021, 28.10.2021, 02.09.2021.</p>	<p>Positive Opinion adopted by consensus on 10.02.2022.</p>
<p>PRAC Led</p> <p>Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0028</p> <p>Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Hans Christian Siersted, PRAC-CHMP liaison: Sinan B. Sarac, "Submission of an updated RMP version 2.3 to include myocarditis and pericarditis as an important identified risk, as requested by PRAC as an outcome of the myocarditis and pericarditis signal assessment procedure."</p> <p>Opinion adopted on 10.02.2022.</p> <p>Request for Supplementary Information adopted on 02.12.2021, 28.10.2021, 02.09.2021.</p>	<p>Positive Opinion adopted by consensus on 10.02.2022.</p>
<p>PRAC Led</p> <p>Stelara - ustekinumab - EMEA/H/C/000958/II/0091</p> <p>Janssen-Cilag International N.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Submission of the final safety registry report of CNTO1275PSO4007 "Pregnancy Research Initiative: Exposure to ustekinumab during pregnancy: A review and analysis of birth outcomes from the Swedish, Danish and Finnish medical birth registers." Consequently, the RMP version 22.1 has been updated."</p> <p>Request for Supplementary Information adopted on 10.02.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>PRAC Led</p> <p>Vargatef - nintedanib -</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

EMA/H/C/002569/II/0044

Boehringer Ingelheim International GmbH,
Rapporteur: Sinan B. Sarac, PRAC Rapporteur:
Georgia Gkegka, PRAC-CHMP liaison:
Konstantina Alexopoulou, "Submission of an updated RMP version 10.0 in order to remove safety concerns that were classified as important identified risks, important potential risks and missing information, based on cumulative post-marketing experience. The MAH is also proposing an update of the ATC code, an update of post-marketing exposure, the removal of adverse event follow-up forms and an update of search strategies."
Request for Supplementary Information adopted on 10.02.2022.

PRAC Led

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -
EMA/H/C/005675/II/0038**

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, "Submission of the final report from study MS1222-0003 "Assessment of anti-PF4 antibodies prior to, and following, vaccination with AZD1222" listed as a category 3 study in the RMP. This is a study where sera of vaccinated individuals in study D8110C00001 are tested to elucidate whether vaccination with Vaxzevria leads to increased levels of circulating anti-PF4 antibodies, a key component of the hypothesised mechanism underlying thrombosis with thrombocytopenia syndrome (TTS)."
Request for Supplementary Information adopted on 10.02.2022, 28.10.2021.

Request for supplementary information adopted with a specific timetable.

PRAC Led

WS2078**Lixiana-EMA/H/C/002629/WS2078/0034
Roteas-EMA/H/C/004339/WS2078/0020**

Daiichi Sankyo Europe GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "C.I.13: Submission of the final report from study ETNA-VTE-EUROPE (DSE-EDO-05-14-EU), listed as a category 3 study in the RMP. This is a Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients with Venous

Positive Opinion adopted by consensus on 24.02.2022.

Thromboembolism in Europe. The RMP version 12.0 has also been submitted.”
Opinion adopted on 24.02.2022.
Request for Supplementary Information adopted on 14.10.2021.

PRAC Led
WS2151
Aflunov-
EMA/H/C/002094/WS2151/0071
Foclivia-
EMA/H/C/001208/WS2151/0068
Seqirus S.r.l, Lead Rapporteur: Armando Genazzani, Lead PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, “Submission of an updated RMP version 3.9 in order to align safety concerns for both products AFLUNOV and FOCLIVIA. Module on 'Epidemiology of the indication and target population' and section on 'use in pregnancy and lactation' are updated. Some potential risks have been reclassified following the definition as per GVP Module V rev.2. Reference to adverse drug reaction follow-up forms for routine pharmacovigilance activity are removed.”
Request for Supplementary Information adopted on 10.02.2022, 28.10.2021.

Request for supplementary information adopted with a specific timetable.

PRAC Led
WS2191
Incresync-
EMA/H/C/002178/WS2191/0040
Vipdomet-
EMA/H/C/002654/WS2191/0036
Vipidia-EMA/H/C/002182/WS2191/0029
Takeda Pharma A/S, Lead PRAC Rapporteur: Menno van der Elst, “Submission of a consolidated RMP version 11 for Vipidia, Vipdomet and Incresync in order to:
- Update the RMPs for Alogliptin, Alogliptin/Pioglitazone fixed dose combination (FDC) and Alogliptin/Metformin fixed dose combination (FDC) to consolidate within a single RMP as committed within the PSUR procedure (PSUSA/00010061/202104).
- Following review of cumulative safety data, removal of a number of safety concerns is done based on GVP Module V, Risk Management Systems (revision 2) guidelines.
- Remove the target follow-up Questionnaires of Severe Hypersensitivity and skin reactions,

Request for supplementary information adopted with a specific timetable.

Pancreatitis, Hepatic events and follow-up gastrointestinal events and infections from Alogliptin and Alo/Met RMPs.

- Reflect the removal of the inverted black triangle as agreed as part of the alogliptin renewal procedure (EMA/H/C/002178/R/0023) for Alogliptin and the FDC Alogliptin/Metformin. The black triangle was already removed from the FDC Alogliptin/Pioglitazone RMP as part of the Type II variation (EMA/H/C/002178/II/0029)."

Request for Supplementary Information adopted on 10.02.2022.

PRAC Led

WS2192

Dovato-EMA/H/C/004909/WS2192/0026

Juluca-EMA/H/C/004427/WS2192/0040

Tivicay-EMA/H/C/002753/WS2192/0075

Triumeq-

EMA/H/C/002754/WS2192/0099

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Ingrid Wang, "Update of section 4.8 of the SmPC to add "completed suicide" to the list of adverse drug reactions (ADRs) with frequency "rare" in the dolutegravir (Tivicay), dolutegravir/abacavir/lamivudine (Triumeq) and dolutegravir/lamivudine (Dovato) following the finalisation of PSUSA procedure EMA/H/C/PSUSA/00010075/202101 (reporting period 17 Jan 2020 to 16 Jan 2021) based on reports of completed suicide from participants exposed to Dolutegravir containing regimen in ViiV Healthcare-sponsored clinical trials. As the changes impact all Dolutegravir containing products, the MAH did a worksharing procedure to include Juluca (Dolutegravir/Rilpivirine) product in accordance with Article 20 (worksharing procedure) of Commission Regulation (EC) 1234/2008. The Package Leaflet are updated accordingly." Opinion adopted on 10.02.2022.

Positive Opinion adopted by consensus on 10.02.2022.

PRAC Led

WS2196

Glyxambi-

EMA/H/C/003833/WS2196/0042

Jardiance-

EMA/H/C/002677/WS2196/0063

Request for supplementary information adopted with a specific timetable.

Synjardy-**EMA/H/C/003770/WS2196/0060**

Boehringer Ingelheim International GmbH, Lead PRAC Rapporteur: Eva A. Segovia, "Update of section 4.4 of the SmPC to delete the warning on 'lower limb amputations' as a consequence of the results from the final meta-analysis report of PASS 1245.171 'A meta-analysis of amputation risk in empagliflozin studies (1245.25, 1245.110, 1245.121)' (included as a category 3 study in the RMP). The Package Leaflet has been updated accordingly. Updated RMP versions have also been submitted; version 17 for Jardiance, version 11 for Synjardy and version 6 for Glyxambi." Request for Supplementary Information adopted on 10.02.2022.

B.5.5. CHMP-CAT assessed procedures

Kymriah - tisagenlecleucel -**EMA/H/C/004090/II/0049/G, Orphan, ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinators: Ingrid Wang, Ewa Balkowiec Iskra
Opinion adopted on 24.02.2022, 17.02.2022.

Positive Opinion adopted by consensus on 24.02.2022.

WS2194**Tecartus-****EMA/H/C/005102/WS2194/0018****Yescarta-****EMA/H/C/004480/WS2194/0048**

Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus
Request for Supplementary Information adopted on 10.02.2022.

Request for supplementary information adopted with a specific timetable.

WS2197**Tecartus-****EMA/H/C/005102/WS2197/0017****Yescarta-****EMA/H/C/004480/WS2197/0047**

Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus
Opinion adopted on 24.02.2022, 18.02.2022.

Positive Opinion adopted by consensus on 24.02.2022.

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

PRAC Led Yescarta - axicabtagene ciloleucel - EMA/H/C/004480/II/0040, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller- Berghaus, CHMP Coordinator: Jan Mueller- Berghaus, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Sinan B. Sarac, "Submission of the final study report for the non-interventional study KT-EU-471-0116 (Quantitative Testing of Healthcare Provider Knowledge about Yescarta (axicabtagene ciloleucel) Risk Minimisation Measures) in fulfilment of an additional pharmacovigilance activity (category 3) listed in the EU Risk Management Plan for Yescarta." Opinion adopted on 24.02.2022, 18.02.2022. Request for Supplementary Information adopted on 10.09.2021.	Positive Opinion adopted by consensus on 24.02.2022.
---	---

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2136 Esperoct- EMA/H/C/004883/WS2136/0009 NovoEight- EMA/H/C/002719/WS2136/0039 Novo Nordisk A/S, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 03.02.2022.	Request for supplementary information adopted with a specific timetable.
WS2148/G Hexacima- EMA/H/C/002702/WS2148/0122/G Hexyon- EMA/H/C/002796/WS2148/0126/G Sanofi Pasteur, Lead Rapporteur: Jan Mueller- Berghaus Opinion adopted on 10.02.2022. Request for Supplementary Information adopted on 09.12.2021.	Positive Opinion adopted by consensus on 10.02.2022.
WS2168 Lyrica-EMA/H/C/000546/WS2168/0114 Pregabalin Pfizer-	Request for supplementary information adopted with a specific timetable.

EMA/H/C/003880/WS2168/0043

Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, "To update SmPC sections 4.4 and 4.8 to reflect new data on suicidal ideation following the review of the data provided in LEG 007 and 054. The package leaflet has been updated accordingly."
Request for Supplementary Information adopted on 17.02.2022.

WS2171**Glyxambi-****EMA/H/C/003833/WS2171/0040****Synjardy-****EMA/H/C/003770/WS2171/0058**

Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "To update section 4.8 of the SmPC and section 4 of the PL to include the side effect 'constipation' in order to align with the Jardiance PI following approval of EMA/H/C/002677/II/0055."
Request for Supplementary Information adopted on 03.02.2022, 02.12.2021.

Request for supplementary information adopted with a specific timetable.

WS2200**Glyxambi-****EMA/H/C/003833/WS2200/0041****Synjardy-****EMA/H/C/003770/WS2200/0059**

Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "To update sections 4.2, 4.4 and 5.1 of the SmPC to propose a modification of the eGFR threshold in the EU PIs for the fixed dose combinations containing empagliflozin, for Synjardy (empagliflozin/metformin) and Glyxambi (empagliflozin/linagliptin) to allow for use of these empagliflozin containing products in patients with T2DM and high cardiovascular risk and an eGFR of ≥ 30 ml/min/1.73 m². This is in line with the changed eGFR threshold for Jardiance (empagliflozin) which received a Positive Opinion on 16 Sep 2021 for the assessment of variation EMA/H/C/002677/II/0057.
Additionally, some editorial changes are also proposed in the revised Synjardy and Glyxambi Product Information. Furthermore, only for Synjardy, Annex A is also suggested to be updated with minor editorial changes.
Finally, the MAH took the opportunity to submit

Positive Opinion adopted by consensus on 10.02.2022.

some Minor Linguistic Changes to Synjardy and Glyxambi Product Information for several countries, as detailed below:

- Glyxambi: SV, ES, FR, PL, HU and HR.
- Synjardy: FR, DE, SV, PL, MT, ET, IT, ES, NL, FI and HR.”

Opinion adopted on 10.02.2022.

WS2203

Kinzalmono-

EMA/H/C/000211/WS2203/0117

Micardis-

EMA/H/C/000209/WS2203/0121

Pritor-EMA/H/C/000210/WS2203/0130

Boehringer Ingelheim International GmbH, Lead Rapporteur: Armando Genazzani, “To introduce several minor linguistic and editorial changes in the PI in all the EEA languages in alignment with the English PI, following the EMA recommendation to perform a full linguistic review of the PI in all EEA languages.

In addition, the MAH has implemented the updated QRD template version 10.2 in all EEA languages including the English PI, for the products Pritor and Kinzalmono.”

Opinion adopted on 03.02.2022.

Positive Opinion adopted by consensus on 03.02.2022.

WS2207

Copalia HCT-

EMA/H/C/001159/WS2207/0096

Dafiro HCT-

EMA/H/C/001160/WS2207/0098

Exforge HCT-

EMA/H/C/001068/WS2207/0095

Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, “To bring the annexes in line with the current QRD template v10.2. In addition, the MAH has taken the opportunity to update the local contact details for the UK (Northern Ireland).”

Opinion adopted on 03.02.2022.

Positive Opinion adopted by consensus on 03.02.2022.

WS2213/G

Aprovel-

EMA/H/C/000141/WS2213/0189/G

Karvea-

EMA/H/C/000142/WS2213/0191/G

sanofi-aventis groupe, Lead Rapporteur: Maria Concepcion Prieto Yerro,

Request for Supplementary Information adopted on 17.02.2022.

Request for supplementary information adopted with a specific timetable.

B.5.9. Information on withdrawn type II variation / WS procedure

Nordimet - methotrexate -**EMA/H/C/003983/II/0021/G**

Nordic Group B.V., Rapporteur: Bruno Sepodes
Request for Supplementary Information adopted
on 13.01.2022.

Withdrawal request submitted on 08.02.2022.

The MAH withdrew the procedure on
08.02.2022.

Plenadren - hydrocortisone -**EMA/H/C/002185/II/0034**

Takeda Pharmaceuticals International AG,
Rapporteur: Kristina Dunder, "Update of section
4.8 of the SmPC to add bradycardias a new ADR
with frequency unknown."

Request for Supplementary Information adopted
on 28.10.2021.

Withdrawal request submitted on 10.02.2022.

The MAH withdrew the procedure on
10.02.2022.

B.5.10. Information on type II variation / WS procedure with revised timetable

PRAC Led**Otezla - apremilast -****EMA/H/C/003746/II/0038**

Amgen Europe B.V., Rapporteur: Peter Kiely,
PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP
liaison: Maria Concepcion Prieto Yerro, "C.I.13 -
Submission of the final study report (CSR) from
PsOBEST Registry, listed as a category 3 study in
the RMP. This is an observational study to
assess the long-term safety and effectiveness of
apremilast in routine clinical practice in
Germany.

The RMP version 14.0 has also been submitted."

Request for Supplementary Information adopted
on 30.09.2021.

Request for an extension to the clock stop to
respond to the RSI adopted in September 2021.

The CHMP agreed to the request by the
applicant.

HEPLISAV B - hepatitis B surface antigen -**EMA/H/C/005063/II/0010**

Dynavax GmbH, Rapporteur: Filip Josephson
Request for Supplementary Information adopted
on 14.10.2021.

Request for an extension to the clock stop to
respond to the RSI adopted in October 2021.

The CHMP agreed to the request by the
applicant.

PRAC Led

VPRIV - velaglucerase alfa -

EMA/H/C/001249/II/0049, Orphan

Takeda Pharmaceuticals International AG,

Rapporteur: Martina Weise, PRAC Rapporteur:

Martin Huber, PRAC-CHMP liaison: Martina

Weise, "Submission of final physician data study

results for PASS study "Evaluation of the

Effectiveness of Risk Minimisation Measures: A

Survey among Health Care Professionals and

Patient/Caregivers to Assess their Knowledge

and Attitudes on Prescribing and Home

Administration Conditions of Velaglucerase

Alpha (VPRIV) in 6 European Countries"

(EUPASS 14255)"

Request for Supplementary Information adopted

on 02.12.2021, 08.07.2021, 11.02.2021,

26.11.2020.

Request for an extension to the clock stop to respond to the RSI adopted in December 2021.

The CHMP agreed to the request by the applicant.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -

EMA/H/C/005675/II/0031

AstraZeneca AB, Rapporteur: Sol Ruiz,

"Submission of the final study report for

MS1222-0002 "In Vitro Assay to Determine

Release of Spike Protein From Transduced Cells"

to fulfil the imposed study as reflected in Annex

II of the product information and the RMP. As a

result, Annex II of the product information is

being updated to remove this study.

The MAH is taking the opportunity to provide

two additional studies linked to support the

investigation on the platelet activation: the final

study report for MS1222-0001 "Computational

Prediction of Spike Protein Interaction with

Platelet Factor 4 (PF4)" which is the first report

requested within the required studies for "in

vitro interaction of AZD1222 or spike protein

with PF4 and/or platelets" as reflected in the

RMP; and the study report for 520447

"Investigative Vaccine Study in the Mouse" to

evaluate spike protein levels and haematology

parameters."

Request for Supplementary Information adopted

on 13.01.2022, 23.09.2021.

Request for an extension to the clock stop to respond to the RSI adopted in January 2022.

The CHMP agreed to the request by the applicant.

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

sodium phenylbutyrate /

ursodoxicoltaurine - EMEA/H/C/005901,

Orphan

Amylyx Pharmaceuticals EMEA B.V., treatment of amyotrophic lateral sclerosis (ALS)

gadopiclenol - EMEA/H/C/005626

for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate).

nirsevimab - EMEA/H/C/005304

Accelerated review

prevention of RSV lower respiratory tract infection.
immunise infants from birth entering their first Respiratory Syncytial Virus (RSV) season for the prevention of RSV lower respiratory tract disease.

dabigatran etexilate - EMEA/H/C/005922

prevention of venous thromboembolic events

dapagliflozin - EMEA/H/C/006006

treatment of type 2 diabetes mellitus, heart failure and chronic kidney disease

pegunigalsidase alfa - EMEA/H/C/005618,

Orphan

Chiesi Farmaceutici S.p.A., treatment of Fabry disease

daprodustat - EMEA/H/C/005746

treatment of anaemia associated with chronic kidney disease (CKD) in adults

in vitro diagnostic medical device -

EMEA/H/D/006078

detection of PD-L1 protein

sitagliptin / metformin hydrochloride -

EMEA/H/C/005778

treatment of type 2 diabetes mellitus

teclistamab - EMEA/H/C/005865, Orphan

Accelerated review

Janssen-Cilag International N.V., treatment of relapsed or refractory multiple myeloma

filgrastim - EMEA/H/C/005888

Reduction in the duration of neutropenia and the incidence of febrile neutropenia, indicated for the mobilisation of peripheral blood progenitor cells and persistent neutropenia in patients with advanced HIV infection

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

asciminib - EMEA/H/C/005605, Orphan

Novartis Europharm Limited, treatment of Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP)

List of Questions adopted on 11.11.2021.

dimethyl fumarate - EMEA/H/C/005963

treatment of multiple sclerosis

List of Questions adopted on 27.01.2022.

lenacapavir - EMEA/H/C/005638

treatment of human immunodeficiency virus type 1 (HIV-1) infection

List of Questions adopted on 16.12.2021.

maribavir - EMEA/H/C/005787, Orphan

Shire Pharmaceuticals Ireland Limited, treatment of cytomegalovirus (CMV) infection

List of Questions adopted on 14.10.2021.

mosunetuzumab - EMEA/H/C/005680, Orphan

Roche Registration GmbH, refractory follicular lymphoma (FL)

List of Questions adopted on 25.01.2022.

Procysbi - mercaptamine - EMEA/H/C/002465/X/0035, Orphan

Chiesi Farmaceutici S.p.A., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga,

"Extension application to introduce a new pharmaceutical form associated with two new strengths (75 and 300 mg gastro-resistant granules). The RMP (version 7.2) is updated in accordance."

List of Questions adopted on 11.11.2021.

ranibizumab - EMEA/H/C/005019

The treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularisation (CNV)

List of Questions adopted on 11.11.2021.

RINVOQ - upadacitinib -**EMEA/H/C/004760/X/0012/G**

AbbVie Deutschland GmbH & Co. KG,

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Extension application to add a new strength (45 mg) of the prolonged-release tablets, grouped with a type II variation (C.I.6.a) to include the treatment of adults with moderately to severely active ulcerative colitis who had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent; as a consequence of the EoI, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance.

The RMP (version 6.0) has also been submitted."

List of Questions adopted on 27.01.2022.

valoctocogene roxaparvovec -**EMEA/H/C/005830, Orphan, ATMP**

BioMarin International Limited, treatment of severe haemophilia A

List of Questions adopted on 05.11.2021.

sorafenib - EMEA/H/C/005921

treatment of hepatocellular carcinoma and renal cell carcinoma

List of Questions adopted on 11.11.2021.

efgartigimod alfa - EMEA/H/C/005849,**Orphan**

Argenx, treatment of generalised Myasthenia Gravis (gMG)

List of Questions adopted on 16.12.2021.

B.6.4. Annual Re-assessments: timetables for adoption

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

**Abecma - idecabtagene vicleucel -
EMA/H/C/004662/R/0014, Orphan,
ATMP**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Rune Kjekken, CHMP Coordinator: Ingrid Wang,
PRAC Rapporteur: Annika Folin

**Alecensa - alectinib -
EMA/H/C/004164/R/0039**

Roche Registration GmbH, Rapporteur: Filip
Josephson, Co-Rapporteur: Sinan B. Sarac,
PRAC Rapporteur: Jana Lukacisinova

**Blenrep - belantamab mafodotin -
EMA/H/C/004935/R/0010, Orphan**

GlaxoSmithKline (Ireland) Limited, Rapporteur:
Johanna Lähteenvuo, Co-Rapporteur: Blanca
Garcia-Ochoa, PRAC Rapporteur: Annika Folin

**Dovprela - pretomanid -
EMA/H/C/005167/R/0010, Orphan**

Mylan IRE Healthcare Limited, Rapporteur: Filip
Josephson, PRAC Rapporteur: Liana Gross-
Martirosyan

**Elebrato Ellipta - fluticasone furoate /
umeclidinium / vilanterol -
EMA/H/C/004781/R/0026**

GlaxoSmithKline Trading Services Limited,
Duplicate, Duplicate of Trelegy Ellipta,
Rapporteur: Peter Kiely, Co-Rapporteur: Janet
Koenig, PRAC Rapporteur: Annika Folin

**Hepcludex - bulevirtide -
EMA/H/C/004854/R/0013, Orphan**

Gilead Sciences Ireland Unlimited Company,
Rapporteur: Filip Josephson, PRAC Rapporteur:
Adam Przybylkowski

**Idefirix - imlifidase -
EMA/H/C/004849/R/0007, Orphan**

Hansa Biopharma AB, Rapporteur: Martina
Weise, Co-Rapporteur: Kristina Dunder, PRAC
Rapporteur: Menno van der Elst

**Nyxoid - naloxone -
EMA/H/C/004325/R/0014**

Mundipharma Corporation (Ireland) Limited,
Rapporteur: Bruno Sepodes, Co-Rapporteur:
Elita Poplavska, PRAC Rapporteur: Liana Gross-
Martirosyan

**Ontruzant - trastuzumab -
EMA/H/C/004323/R/0040**

Samsung Bioepis NL B.V., Rapporteur: Karin
Janssen van Doorn, Co-Rapporteur: Elita
Poplavska, PRAC Rapporteur: Brigitte Keller-
Stanislawski

**Ritonavir Mylan - ritonavir -
EMA/H/C/004549/R/0015**

Mylan Pharmaceuticals Limited, Generic,
Generic of Norvir, Rapporteur: John Joseph
Borg, PRAC Rapporteur: Liana Gross-
Martirosyan

**Tacforius - tacrolimus -
EMA/H/C/004435/R/0010**

Teva B.V., Generic, Generic of Advagraf,
Rapporteur: Daniela Philadelphia, PRAC
Rapporteur: Ronan Grimes

**Translarna - ataluren -
EMA/H/C/002720/R/0067, Orphan**

PTC Therapeutics International Limited,
Rapporteur: Johann Lodewijk Hillege, PRAC
Rapporteur: Liana Gross-Martirosyan

**Trelegy Ellipta - fluticasone furoate /
umeclidinium / vilanterol -
EMA/H/C/004363/R/0023**

GlaxoSmithKline Trading Services Limited,
Rapporteur: Peter Kiely, Co-Rapporteur: Janet
Koenig, PRAC Rapporteur: Annika Folin

**Tremfya - guselkumab -
EMA/H/C/004271/R/0033**

Janssen-Cilag International N.V., Rapporteur:
Agnes Gyurasics, Co-Rapporteur: Peter Kiely,
PRAC Rapporteur: Brigitte Keller-Stanislawski

**VeraSeal - human fibrinogen / human
thrombin - EMA/H/C/004446/R/0018**

Instituto Grifols, S.A., Rapporteur: Andrea
Laslop, Co-Rapporteur: Ewa Balkowiec Iskra,
PRAC Rapporteur: Amelia Cupelli

**Zejula - niraparib -
EMA/H/C/004249/R/0034, Orphan**

GlaxoSmithKline (Ireland) Limited, Rapporteur:
Ingrid Wang, Co-Rapporteur: Alexandre Moreau,
PRAC Rapporteur: Jan Neuhauser

**Zubsolv - buprenorphine / naloxone -
EMA/H/C/004407/R/0019**

Accord Healthcare S.L.U., Rapporteur: Peter

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Brukinsa - zanubrutinib -

EMA/H/C/004978/II/0003

BeiGene Ireland Ltd, Rapporteur: Sinan B.

Sarac, Co-Rapporteur: Johanna Lähteenvuo,

PRAC Rapporteur: Menno van der Elst,

“Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) based on results from study BGB-3111-304; an ongoing, international, Phase 3, open-label, multiple-cohort, randomized study designed to evaluate the efficacy of zanubrutinib versus B+R in patients with previously untreated CLL/SLL, and study BGB-3111-305; an ongoing, international Phase 3, open-label, randomized study of zanubrutinib versus ibrutinib with R/R CLL/SLL.

As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1 and 5.2 of the SmPC are being updated. The Package Leaflet is updated in accordance.

An updated RMP version 1.1 (specific for the proposed indication CLL/SLL) was also submitted.

In addition, as part of the application, the MAH requested a 1-year extension of the market protection.”

Esbriet - pirfenidone -

EMA/H/C/002154/II/0074

Roche Registration GmbH, Rapporteur: Peter

Kiely, Co-Rapporteur: Johann Lodewijk Hillege,

PRAC Rapporteur: Rhea Fitzgerald, “Extension

of indication to include treatment of ‘advanced’ idiopathic pulmonary fibrosis (IPF) by the deletion of the current qualifier ‘mild to moderate’, based on the results from study MA29957; this is a 52-week Phase IIb, multicentre, randomised, double-blind, placebo-controlled clinical trial in IPF patients with advanced lung function impairment (DLco < 40% of predicted) and at high risk of grade 3

pulmonary hypertension, and additional analyses performed on the original pivotal trials for pirfenidone in IPF.

As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. In addition, the MAH took the opportunity to include information in section 4.4 of the SmPC related to the content of sodium per Esbriet capsule and tablet. The Package Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted.”

**Ronapreve - casirivimab / imdevimab -
EMA/H/C/005814/II/0002**

Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Ulla Wändel Liminga, “Extension of indication to include treatment of COVID-19 in hospitalised patients in adults and adolescents aged 12 years and older weighing at least 40 kg for Ronapreve; as a consequence, sections 4.2, 4.4, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 1.1 of the RMP has also been submitted.”

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

**BLINCYTO - blinatumomab -
EMA/H/C/003731/II/0045, Orphan**

Amgen Europe B.V., Rapporteur: Alexandre Moreau

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0108/G**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

See also B.5.1

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0109/G**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0112/G**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0115/G**

BioNTech Manufacturing GmbH, Rapporteur:
Filip Josephson

**COVID-19 Vaccine Janssen - adenovirus
type 26 encoding the sars-cov-2 spike
glycoprotein -**

EMA/H/C/005737/II/0041/G

Janssen-Cilag International N.V., Rapporteur:
Christophe Focke

Drovelis - drospirenone / estetrol -

EMA/H/C/005336/II/0006/G

Chemical Works of Gedeon Richter Plc. (Gedeon
Richter Plc.), Rapporteur: Kristina Dunder

Dupilumab - dupilumab -

EMA/H/C/004390/II/0059/G

sanofi-aventis groupe, Rapporteur: Jan Mueller-
Berghaus

**Fluenz Tetra - influenza vaccine (live
attenuated, nasal) -**

EMA/H/C/002617/II/0113/G

AstraZeneca AB, Rapporteur: Christophe Focke

GONAL-f - follitropin alfa -

EMA/H/C/000071/II/0154/G

Merck Europe B.V., Rapporteur: Johann
Lodewijk Hillege

Jivi - damoctocog alfa pegol -

EMA/H/C/004054/II/0023

Bayer AG, Rapporteur: Thalia Marie Estrup
Blicher

Kanuma - sebelipase alfa -

EMA/H/C/004004/II/0036/G, Orphan

Alexion Europe SAS, Rapporteur: Karin Janssen
van Doorn

Lydisilka - drospirenone / estetrol -

EMA/H/C/005382/II/0006/G

Estetra SRL, Duplicate, Duplicate of Drovelis,
Rapporteur: Kristina Dunder

MabThera - rituximab -

EMA/H/C/000165/II/0189/G

Roche Registration GmbH, Rapporteur: Sinan B.
Sarac

Mekinist - trametinib -

EMA/H/C/002643/II/0053/G

Novartis Europharm Limited, Rapporteur: Paula
Boudewina van Hennik

**MenQuadfi - meningococcal group a, c,
w135 and y conjugate vaccine -
EMA/H/C/005084/II/0016/G**

Sanofi Pasteur, Rapporteur: Andrea Laslop

Nityr - nitisinone -

EMA/H/C/004582/II/0011

Cycle Pharmaceuticals (Europe) Limited,
Generic, Generic of Orfadin, Rapporteur: Peter
Kiely

Nucala - mepolizumab -

EMA/H/C/003860/II/0049

GlaxoSmithKline Trading Services Limited,
Rapporteur: Peter Kiely

Pandemic influenza vaccine H5N1

**AstraZeneca - pandemic influenza vaccine
(h5n1) (live attenuated, nasal) -**

EMA/H/C/003963/II/0048/G

AstraZeneca AB, Rapporteur: Jan Mueller-
Berghaus

**Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-
((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-
3,3-dimethyl-2-(2,2,2-trifluoroacetamido)
butanoyl)-6,6-dimethyl-3-
azabicyclo[3.1.0]hexane-2-carboxamide /
ritonavir - EMA/H/C/005973/II/0001/G**
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel
Race

**Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-
((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-
3,3-dimethyl-2-(2,2,2-trifluoroacetamido)
butanoyl)-6,6-dimethyl-3-
azabicyclo[3.1.0]hexane-2-carboxamide /
ritonavir - EMA/H/C/005973/II/0002**
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel
Race

**Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-
((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-
3,3-dimethyl-2-(2,2,2-trifluoroacetamido)
butanoyl)-6,6-dimethyl-3-
azabicyclo[3.1.0]hexane-2-carboxamide /
ritonavir - EMA/H/C/005973/II/0003/G**
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel
Race

RoActemra - tocilizumab -

EMA/H/C/000955/II/0108

Roche Registration GmbH, Rapporteur: Jan

Mueller-Berghaus

**Shingrix - herpes zoster vaccine
(recombinant, adjuvanted) -
EMA/H/C/004336/II/0052/G**

GlaxoSmithkline Biologicals SA, Rapporteur:
Christophe Focke

**Soliris - eculizumab -
EMA/H/C/000791/II/0121, Orphan**

Alexion Europe SAS, Rapporteur: Blanca Garcia-
Ochoa

**Spikevax - COVID-19 mRNA vaccine
(nucleoside-modified) -
EMA/H/C/005791/II/0054/G**

Moderna Biotech Spain, S.L., Rapporteur: Jan
Mueller-Berghaus

**Synflorix - pneumococcal polysaccharide
conjugate vaccine (adsorbed) -
EMA/H/C/000973/II/0171/G**

GlaxoSmithkline Biologicals SA, Rapporteur:
Kristina Dunder

**Trulicity - dulaglutide -
EMA/H/C/002825/II/0062/G**

Eli Lilly Nederland B.V., Rapporteur: Martina
Weise

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S
[recombinant]) -
EMA/H/C/005675/II/0064/G**

AstraZeneca AB, Rapporteur: Sol Ruiz

**Vyxeos liposomal - daunorubicin /
cytarabine -
EMA/H/C/004282/II/0028/G, Orphan**

Jazz Pharmaceuticals Ireland Limited,
Rapporteur: Johanna Lähteenvuo

**Wegovy - semaglutide -
EMA/H/C/005422/II/0001/G**

Novo Nordisk A/S, Rapporteur: Johann Lodewijk
Hillege

**Zinplava - bezlotoxumab -
EMA/H/C/004136/II/0031**

Merck Sharp & Dohme B.V., Rapporteur: Jan
Mueller-Berghaus

**WS2193
Candidas-
EMA/H/C/000379/WS2193/0075
Cubicin-EMA/H/C/000637/WS2193/0081**

Invanz-EMA/H/C/000389/WS2193/0065

Ivemend-

EMA/H/C/000743/WS2193/0046

Noxafil-EMA/H/C/000610/WS2193/0069

PREVYMIS-

EMA/H/C/004536/WS2193/0025

Recarbrio-

EMA/H/C/004808/WS2193/0013

Sivextro-

EMA/H/C/002846/WS2193/0044

Temodal-

EMA/H/C/000229/WS2193/0096

Zerbaxa-

EMA/H/C/003772/WS2193/0037

Merck Sharp & Dohme B.V., Lead Rapporteur:

Filip Josephson

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adempas - riociguat -

EMA/H/C/002737/II/0035, Orphan

Bayer AG, Rapporteur: Johann Lodewijk Hillege, "Submission of the final report from study REPLACE (#18588/PH-41313). This is a prospective, randomized, international, multicenter, double-arm, controlled, open-label phase 4 study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), but not at treatment goal."

Braftovi - encorafenib -

EMA/H/C/004580/II/0026

Pierre Fabre Medicament, Rapporteur: Janet Koenig, "Update of section 4.2 of the SmPC in order to introduce a new scheme of encorafenib dose reduction recommendations for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, by replacing the second dose reduction level of 200 mg once daily by 225 mg once daily; based on results from simulation report (ARRA-CSC-104). In addition, the MAH took the opportunity to introduce an update of the user instructions in the Package Leaflet for increased clarity."

Cibinqo - abrocitinib -

EMA/H/C/005452/II/0002

Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, "Update of section 4.5 of the SmPC based on results from Drug-Drug Interaction (DDI) study B7451061; A phase 1, randomized, crossover study to evaluate relative Bioavailability of abrocitinib Oral suspension and effect of an Acid-reducing agent on the Bioavailability of abrocitinib Commercial tablet and to assess The taste of abrocitinib oral Formulations in healthy adult Participants aged 18 to 55 years of age."

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0111**

See 9.1 and B.5.2

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC of Comirnaty 30 microgram/dose in order to change posology recommendations for booster use from "individuals 18 years of age and older" to "individuals 12 years of age and older", based on real world evidence collected by the Ministry of Health of Israel and published literature data. The Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

**Cosentyx - secukinumab -
EMA/H/C/003729/II/0084**

Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola, "Update of section 4.8 of the SmPC in order to add the new ADR "dyshidrotic eczema" with the frequency Uncommon based on post-marketing data. The section 4 of Package Leaflet is updated accordingly."

**Cotellic - cobimetinib -
EMA/H/C/003960/II/0025**

Roche Registration GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC based on final results from study GO29665 (iMATRIX_cobimetinib) which corresponds to study 4 of PIP EMA-C-001425-PIP01-13-M05. This is a phase I/II, multicentre, open-label, dose-escalation study of the safety, efficacy and pharmacokinetics of cobimetinib in paediatric and young adult patients with previously treated solid tumours. The section 2 of the Package Leaflet is updated accordingly. In addition, final results of the GO29665 study are submitted in line with Article 46 of Regulation

(EC) No 1901/2006.”

Edurant - rilpivirine -

EMA/H/C/002264/II/0040

Janssen-Cilag International N.V., Rapporteur:
Paula Boudewina van Hennik, “Update of section 4.8 of the SmPC in order to remove several of the treatment emergent clinical laboratory abnormalities from the list of adverse drug reactions (ADRs). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

Hepcludex - bulevirtide -

EMA/H/C/004854/II/0011, Orphan

Gilead Sciences Ireland Unlimited Company,
Rapporteur: Filip Josephson, “Update of section 4.4 of the SmPC in order to remove the existing warnings on ‘Increase of bile salts’ and ‘Administration site reactions’, and add them as ADRs in section 4.8 of the SmPC as well as the addition of a new ADR: hypersensitivity reactions (including anaphylactic reaction) and editing existing ADRs following a safety review based on pooled data from clinical trials and post-marketing experience. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to make it in line with the EU QRD template v10.2.”

Kineret - anakinra -

EMA/H/C/000363/II/0087

Swedish Orphan Biovitrum AB (publ),
Rapporteur: Thalia Marie Estrup Blicher, “C.I.13: Submission of the final report from study SAVE-MORE, as requested as part of procedure EMA/H/C/000363/II/086. This is a prospective, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of the early start of anakinra treatment guided by suPAR in patients with LRTI by SARS-CoV-2 in improving the clinical state of COVID-19 patients over 28 days as measured by the ordinal scale of the 11-point WHO-CPS.”

Luveris - lutropin alfa -

EMA/H/C/000292/II/0091

Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher, “Update of sections 4.1, 4.2, 5.1

and 5.2 of the SmPC in order to update details regarding the definition of severe LH and FSH deficiency, to clarify follicular development as the treatment target and selection of the most adequate Medically Assisted Reproduction procedure for healthcare providers and to clarify the pharmacokinetic and pharmacodynamic properties of the two gonadotropins, in alignment with the variation EMEA/H/C/000714/II/0075 for Pergoveris, based on a systematic literature search and review. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

Nimenrix - meningococcal group A, C, W135 and Y conjugate vaccine -

EMEA/H/C/002226/II/0115

Pfizer Europe MA EEIG, Rapporteur: Ingrid Wang, “Update of section 5.1 of the SmPC, as requested by the CHMP following the conclusion of procedure P46/055, in order to include long-term antibody persistence data from study MenACWY-TT-104: a phase III, randomised, open, controlled, multicentre, primary vaccination study to evaluate the immunogenicity and persistence of 1 and 2 doses of meningococcal conjugate vaccine MenACWY-TT in toddlers (after 1 month and up to 5 years) and to demonstrate non-inferiority of co-administration of MenACWY-TT and 13-valent pneumococcal conjugate vaccine Prevenar 13 versus separate administration of the 2 vaccines. The Annex II has been updated accordingly.”

Revlimid - lenalidomide -

EMEA/H/C/000717/II/0122

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, “Update of section 4.2 of the SmPC to update the dosage for patients with impaired renal function (severe renal impairment and end stage renal disease) for the follicular lymphoma (FL) indication based on additional PK analysis. In addition, the MAH proposed to update the existing warning in section 4.4 of the SmPC to highlight that male patients should not donate semen or sperm during treatment and for at least seven days after the end of treatment in order to align with

the Revlimid Annex IID requirements for the patient educational brochures and to align with similar wording in the Imnovid (pomalidomide) and Thalidomide BMS (thalidomide) SmPCs. The Package Leaflet is updated accordingly.”

**Ronapreve - casirivimab / imdevimab -
EMA/H/C/005814/II/0001**

See B.5.2

Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.1, 4.4 and 5.1 of the SmPC in order to update information on the in vitro neutralisation activity of casirivimab/imdevimab against the SARS-CoV-2 B.1.1.529 (Omicron) variant.”

**RYBREVANT - amivantamab -
EMA/H/C/005454/II/0001**

Janssen-Cilag International N.V., Rapporteur: Filip Josephson, “Update of section 4.8 of the SmPC in order to add hypokalaemia and hypomagnesaemia to the list of adverse drug reactions (ADRs), with the frequency common, based on an updated analysis of data submitted during the marketing authorisation procedure. The Package Leaflet is updated accordingly. In addition, the MAH proposed to update the current information in section 4.2 of the SmPC to improve clarity and provide more specific guidance. The MAH also took the opportunity to introduce editorial changes in section 4.8 of the SmPC.”

**Somavert - pegvisomant -
EMA/H/C/000409/II/0102**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, “Update of section 5.1 of the SmPC in order to include details on insulin sensitivity based on the results of the ACROSTUDY (A6291010) and additional literature. In addition, the MAH took the opportunity to introduce editorial changes to the list of local representatives in the Package Leaflet.”

**Sprycel - dasatinib -
EMA/H/C/000709/II/0083**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Sinan B. Sarac, “Submission of the final report from study CA180226 PK substudy, as requested in X/0056/G procedure, and the population PK (PPK) analyses conducted to refine the PK characterisation of the dasatinib (BMS-354825) powder for oral suspension

(PFOS) in paediatric patients with Philadelphia chromosome positive (Ph+) chronic phase chronic myeloid leukaemia (CP-CML) or Ph+ acute lymphoblastic leukaemia (ALL).”

Vocabria - cabotegravir -

EMA/H/C/004976/II/0011

ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, “Submission of the final report from study 2021N477482_00. This is an in vitro study to assess the cabotegravir inducing potential on CYP1A2 and 2B6 mRNAs in human hepatocyte cells.”

B.6.10. CHMP-PRAC assessed procedures

Cibinqo - abrocitinib -

EMA/H/C/005452/II/0001

Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, “Update of sections 4.4 and 4.8 of the SmPC based on updated safety data from the Full Cumulative Pool (April 2021 data cut) from the ongoing long-term extension study B7451015. The RMP version v1.0 has also been submitted. In addition, MAH took the opportunity to implement editorial changes in the SmPC and to update the contact details of the local representatives in the Package Leaflet.”

CRYSVITA - burosumab -

EMA/H/C/004275/II/0028, Orphan

Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Update of sections 4.8 and 5.1 of the SmPC in order to update the frequency of the adverse drug reactions, to split immunogenicity data into paediatric and adult populations and to update clinical efficacy in paediatric patients upon request by the CHMP, following PAM procedures P46/006, P46/007 and type II variations II/04 and II/10/G, based on the final results from studies UX023-CL201, UX023-CL205 and UX023-CL301. In addition, the MAH proposes to delete the remaining specific obligation for study UX023-CL205 from the Annex II and requests the switch from a conditional MA to standard MA. The Package Leaflet was updated accordingly. The RMP version 5.0 has also been submitted.”

**Dapivirine Vaginal Ring 25 mg - dapivirine
- EMEA/H/W/002168/II/0015/G**

International Partnership for Microbicides
Belgium AISBL, Rapporteur: Paula Boudewina
van Hennik, PRAC Rapporteur: Jan Neuhauser,
"Submission of the four addenda from studies
IPM 032, MTN-025, IPM 007 and MTN-015 listed
as category 3 studies in the RMP. The data
presented in the addenda are the results of
retrospective next generation sequencing (NGS)
and phenotype susceptibility testing on blood
samples to further assess the potential
development of nonnucleoside reverse
transcriptase inhibitor (NNRTI) resistance in
women with unrecognised or acute HIV-1
infection. The tested samples are all from
women who were initially enrolled in the Phase
III clinical trials IPM 027 and MTN-020 and then
had the option to participate in the open-label
extension (OLE) studies IPM 032 and MTN-025.
If the women became infected with HIV during
any of the trials, they could enrol in the
observational studies IPM 007 and MTN-015.
The RMP version 0.9 has also been submitted.
Additionally, the MAH would like to take the
opportunity to update the EMA on other
commitments outlined in the RMP as additional
risk minimisation measures. These include the
development of a Healthcare Professional Guide
(HCP Guide) and a User Guide with agreed
objectives and key messages."

**Dapivirine Vaginal Ring 25 mg - dapivirine
- EMEA/H/W/002168/II/0016**

International Partnership for Microbicides
Belgium AISBL, Rapporteur: Paula Boudewina
van Hennik, PRAC Rapporteur: Jan Neuhauser,
"Submission of an updated RMP version 0.9 and
Annex II for Dapivirine in order to replace the
current PAES: Phase IV, open label, multicentre
efficacy trial in healthy HIV-negative young
women age 18-25 years (IPM 055), listed as a
category 1 study in the RMP, with the
implementation study: Dapivirine vaginal ring
implementation in a real-world setting in young
women."

**Descovy - emtricitabine / tenofovir
alafenamide - EMEA/H/C/004094/II/0057**

Gilead Sciences Ireland UC, Rapporteur: Bruno
Sepodes, PRAC Rapporteur: Ana Sofia Diniz

Martins, "Submission of the clinical study report and supporting modular summaries for study GS-US-311-1269 'Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen' in fulfilment of the milestone for the category 3 additional pharmacovigilance activity to address the safety concern of long-term safety information in adolescents (missing information) as detailed in the Descovy EU Risk Management Plan (RMP). The RMP version 6.1 has also been submitted."

**EXJADE - deferasirox -
EMA/H/C/000670/II/0082/G**

Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "C.I.13: Submission of the final report from the Calypso study (CICL670F2202) listed as a category 3 study in the RMP. This is a randomized, open-label, multicentre, two arm, Phase II study to evaluate treatment compliance, efficacy and safety of deferasirox (granules) in paediatric patients with iron overload. The RMP version 20.0 has also been submitted.

C.I.11.b: Submission of an updated RMP version 20.0 with the following changes: to remove the risk of 'medication error' from the Exjade RMP and to remove the information related to the discontinuation of Exjade Dispersible Tablets in the EU."

**Kisqali - ribociclib -
EMA/H/C/004213/II/0035**

Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Anette Kirstine Stark, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final Overall Survival (OS) analysis from study A2301 (MONALEESA-2); a Phase III, randomized, double-blind, placebo-controlled, multicentre study of ribociclib in combination with letrozole in postmenopausal women with HR+, HER2-, locoregionally recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease, and based on an updated pooled safety dataset (including the studies MONALEESA-2, MONALEESA-3 and

MONALEESA-7). The Package Leaflet was updated accordingly.

The study is listed as a category 3 study in the RMP, and the submission of the final study report addresses MEA 004.

An updated RMP version 6.0 was also submitted.”

Nulojix - belatacept -

EMA/H/C/002098/II/0079/G

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Veklury - remdesivir -

EMA/H/C/005622/II/0034/G

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová, “Grouping variation to update sections 5.1 and 5.2 of the SmPC as a consequence of the submission of the final component of the Specific Obligation 012 agreed in the renewal of the CMA (EMA/H/C/005622/R/0015) and listed in the Annex II of the Product Information. This submission includes the ACTT-1 final sequencing and phenotyping analysis and the full virology report including activity against variants. The Package Leaflet is updated accordingly. The RMP version 3.1 has also been submitted.”

Xeljanz - tofacitinib -

EMA/H/C/004214/II/0046

Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, “Update of section 5.3 of the SmPC in order to update safety information on reproductive and developmental toxicity based on final study results from An Oral (Gavage) Juvenile Toxicity Study of CP-690,550 in Sprague Dawley Rats (MEA 022) listed as a category 3 study in the RMP.

The RMP version 23.1 has also been submitted.

In addition, the MAH is also taking this opportunity to update the contact details of the local representatives in the Package Leaflet.”

Zepatier - elbasvir / grazoprevir -

EMA/H/C/004126/II/0034

Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, “Submission of the final report from study MK-5172-017, listed as a category 3

study in the RMP. This is a Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with Zepatier in a Prior Clinical Trial. The submission of the study report addresses MEA 002.1. The RMP version 5.1 has also been submitted.”

B.6.11. PRAC assessed procedures

PRAC Led

AJOVY - fremanezumab -

EMA/H/C/004833/II/0029

TEVA GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kirsti Villikka, PRAC-CHMP liaison: Outi Mäki-Ikola, “Submission of an updated RMP version 3.0 in line with the PI changes which were implemented following the assessment of PSUSA/202103 with regards to severe hypersensitivity reactions. The MAH has also taken the opportunity to update the PASS details according to the latest approved PASS protocols.”

PRAC Led

Defitelio - defibrotide -

EMA/H/C/002393/II/0058/G, Orphan

Gentium S.r.l., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, “Grouped application including two type II variations as follows:

C.I.13: Submission of the final study report of the DEFIFrance registry: a national, post-registration observational study of the long-term safety and health outcome of patients treated with Defitelio, including patients with severe hepatic VOD after HSCT. This study is listed as a category 3 study in the RMP, and the submission of the study report addresses LEG/011.3. In addition, the MAH took the opportunity to provide two errata to the clinical study reports of studies #R09-1425 and #2006-05. Consequential changes to RMP version 9.2 have been implemented.

C.I.11: Submission of an updated RMP version 9.2 in order to remove reproductive toxicity as a potential risk.”

PRAC Led

Hepcludex - bulevirtide -

EMA/H/C/004854/II/0012, Orphan

Gilead Sciences Ireland Unlimited Company,
Rapporteur: Filip Josephson, PRAC Rapporteur:
Adam Przybylkowski, PRAC-CHMP liaison: Ewa
Balkowiec Iskra, "Submission of an updated
RMP version 1.2 in order to replace the current
non-interventional registry study, MYR-HDV,
listed as a category 3 required additional
pharmacovigilance activity in the currently RMP,
with the interventional registry study GS-US-
589-6206.

In addition, the MAH is also taking this
opportunity to update the information on
Epidemiology, Clinical Trial Exposure and Post-
authorisation experience."

PRAC Led

Nucala - mepolizumab -

EMA/H/C/003860/II/0048

GlaxoSmithKline Trading Services Limited, PRAC
Rapporteur: Brigitte Keller-Stanislawski,
"Submission of an updated RMP version 9 to
reflect the proposal to stop the enrolment and
to close the pregnancy registry "Mepolizumab
Pregnancy Exposure Study 200870: a phase IV,
prospective, observational, exposure cohort
study of pregnancy outcomes in women
(category 3 post-authorisation measure in the
RMP)". The application also includes details of
the proposed enhanced data collection for all
pregnancies reported as an alternative."

PRAC Led

Rapamune - sirolimus -

EMA/H/C/000273/II/0184

Pfizer Europe MA EEIG, PRAC Rapporteur: Ulla
Wändel Liminga, PRAC-CHMP liaison: Kristina
Dunder, "Submission of the final report from
non-interventional study B1741224, A
Population Based Cohort Study to Monitor the
Safety and Effectiveness of Sirolimus in Patients
With Sporadic Lymphangiomyomatosis (S-
LAM), designated as a category 3 PASS."

PRAC Led

WS2223/G

Glyxambi-

EMA/H/C/003833/WS2223/0043/G

Jardiance-

EMA/H/C/002677/WS2223/0066/G

Synjardy-**EMA/H/C/003770/WS2223/0062/G**

Boehringer Ingelheim International GmbH, Lead Rapporteur: TBC, Lead PRAC Rapporteur: Eva A.

Segovia, PRAC-CHMP liaison: Blanca Garcia-Ochoa, "Grouping of two variations as follows:

C.I.13: Submission of the final report from study PASS 1245.146 listed as a category 3 study in the RMP. This is 'a 5-year enhanced pharmacovigilance surveillance initiative to survey and characterise spontaneous occurrence and experience of ketoacidotic events in patients treated with empagliflozin-containing products'. The RMP has been updated as a consequence.

C.I.11 for RMP: Submission of an updated RMP in order to remove the following safety concerns:

- Bone fracture, classified as an important potential risk and
- Pregnancy/breast-feeding, classified as missing information.

Updated RMP versions 18.0 for Jardiance, 12.0 for Synjardy and 7.0 for Glyxambi were submitted accordingly."

PRAC Led

WS2235**Kispilix-EMA/H/C/004224/WS2235/0050****Lenvima-****EMA/H/C/003727/WS2235/0046**

Eisai GmbH, Lead PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Kristina Dunder, "Update of section 4.8 of the SmPC of Lenvima and Kispilix in order to add colitis to the list of ADRs with frequency uncommon, following PRAC Signal assessment of colitis with lenvatinib (EPITT no: 19691). The Package Leaflets are updated accordingly."

B.6.12. CHMP-CAT assessed procedures

Kymriah - tisagenlecleucel -**EMA/H/C/004090/II/0050, Orphan, ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang

Kymriah - tisagenlecleucel -**EMA/H/C/004090/II/0052, Orphan, ATMP**

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2202/G

Comtan-

EMA/H/C/000171/WS2202/0059/G

Comtess-

EMA/H/C/000170/WS2202/0062/G

Corbilta-

EMA/H/C/002785/WS2202/0028/G

Entacapone Orion-

EMA/H/C/002440/WS2202/0021/G

Levodopa/Carbidopa/Entacapone Orion-

EMA/H/C/002441/WS2202/0036/G

Stalevo-

EMA/H/C/000511/WS2202/0098/G

Orion Corporation, Lead Rapporteur: Outi Mäki-
Ikola

WS2226/G

Aflunov-

EMA/H/C/002094/WS2226/0076/G

Foclivia-

EMA/H/C/001208/WS2226/0074/G

Seqirus S.r.l, Lead Rapporteur: Armando
Genazzani

WS2230

Ebymect-

EMA/H/C/004162/WS2230/0056

Xigduo-EMA/H/C/002672/WS2230/0066

AstraZeneca AB, Lead Rapporteur: Kristina
Dunder

WS2233

Hexacima-

EMA/H/C/002702/WS2233/0127

Hexyon-

EMA/H/C/002796/WS2233/0131

Sanofi Pasteur Europe, Duplicate, Duplicate of
Hexacima, Lead Rapporteur: Jan Mueller-
Berghaus

WS2234/G

Ebymect-

EMA/H/C/004162/WS2234/0055/G

Edistride-

EMA/H/C/004161/WS2234/0052/G

Forxiga-

EMA/H/C/002322/WS2234/0073/G

Qtern-

EMA/H/C/004057/WS2234/0034/G

Xigduo-

EMA/H/C/002672/WS2234/0065/G

AstraZeneca AB, Lead Rapporteur: Johann

Lodewijk Hilleg

WS2236/G

Aflunov-

EMA/H/C/002094/WS2236/0077/G

Foclivia-

EMA/H/C/001208/WS2236/0075/G

Seqirus S.r.l, Lead Rapporteur: Armando

Genazzani

WS2238

Hukyndra-

EMA/H/C/005548/WS2238/0001

Libmyris-

EMA/H/C/005947/WS2238/0001

STADA Arzneimittel AG, Lead Rapporteur: Outi

Mäki-Ikola

WS2248/G

Aflunov-

EMA/H/C/002094/WS2248/0078/G

Foclivia-

EMA/H/C/001208/WS2248/0076/G

Seqirus S.r.l, Lead Rapporteur: Armando

Genazzani

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. Time-Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 21-24 February 2022 CHMP plenary:

Haematology – Hemostaseology

Control of erythrocytosis either as a monotherapy or in combination with cytoreductive therapies in polycythaemia vera patients (SME)

The CHMP denied eligibility to PRIME and adopted the critical summary report.

Neurology

Treatment of non-traumatic subarachnoid haemorrhage (SME)

The CHMP denied eligibility to PRIME and adopted the critical summary report.

Oncology

Treatment of patients with advanced solid tumors that have an NTRK gene fusion who have progressed following treatment with 1 or 2 prior TRK tyrosine kinase inhibitors (TKIs) (with or without prior chemotherapy) and have no satisfactory alternative treatments

The CHMP denied eligibility to PRIME and adopted the critical summary report.

G.2.2. List of procedures starting in February 2022 for March 2022 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address